Timber Pharmaceuticals (TMBR) S-4 20 Feb 20 Registration of securities issued in business combination transactions Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION	9 Months Ended
	Oct. 31, 2019
DOCUMENT AND ENTITY INFORMATION
Entity Registrant Name	BioPharmX Corp
Entity Central Index Key	0001504167
Document Type	S-4
Amendment Flag	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 31, 2019	Jan. 31, 2018
Current assets:
Cash and cash equivalents	$ 3,069	$ 7,576
Accounts receivable, net	4	7
Inventories		10
Prepaid expenses and other current assets	316	388
Total current assets	3,385	7,981
Property and equipment, net	148	109
Other assets	121
Total assets	3,654	8,090
Current liabilities:
Accounts payable	1,363	1,376
Accrued expenses and other current liabilities	934	1,603
Total current liabilities	2,297	2,979
Long-term liabilities:
Long-term liabilities	59	39
Total liabilities	2,356	3,018
Commitments and contingencies (Note 5)
Stockholders' equity:
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of January 31, 2019 and 2018, respectively
Common stock, $0.001 par value; 450,000,000 shares authorized; 218,315,296 and 160,062,509 shares issued and outstanding as of January 31, 2019 and 2018, respectively	9	160
Additional paid-in capital	79,823	66,190
Accumulated deficit	(78,534)	(61,278)
Total stockholders' equity	1,298	5,072
Total liabilities and stockholders' equity	$ 3,654	$ 8,090

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 31, 2019	Apr. 25, 2019	Jan. 31, 2019	Jan. 31, 2018
CONDENSED CONSOLIDATED BALANCE SHEETS
Series A convertible preferred stock, par value	$ 0.001		$ 0.001	$ 0.001
Series A convertible preferred stock, shares authorized	10,000,000		10,000,000	10,000,000
Series A convertible preferred stock, shares issued	0		0	0
Series A convertible preferred stock, shares outstanding	0		0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000		450,000,000	450,000,000
Common stock, shares issued	15,227,891		8,732,612	160,062,509
Common stock, shares outstanding	15,227,891		8,732,612	160,062,509

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended						9 Months Ended		12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenues, net				$ 10				$ 52	$ 57	$ 73
Cost of goods sold				60				80	83	250
Gross margin				(50)				(28)	(26)	(177)
Operating expenses:
Research and development	$ 740			2,228			$ 4,314	7,285	9,079	9,140
Sales and marketing	139			550			572	1,717	2,157	2,415
General and administrative	1,241			1,624			3,534	4,252	5,244	5,144
Total operating expenses	2,120			4,402			8,420	13,254	16,480	16,699
Loss from operations	(2,120)			(4,452)			(8,420)	(13,282)	(16,506)	(16,876)
Change in fair value of warrant liability				42			11	(1)	28	364
Other expense, net	7			20			29	83	(778)	(126)
Loss before provision for income taxes	(2,113)			(4,390)			(8,380)	(13,200)	(17,256)	(16,638)
Provision for income taxes							2	2	2	2
Net loss and comprehensive loss	$ (2,113)	$ (2,646)	$ (3,623)	$ (4,390)	$ (4,410)	$ (4,402)	$ (8,382)	$ (13,202)	$ (17,258)	$ (16,640)
Basic and diluted net loss per share	$ (0.14)			$ (0.57)			$ (0.69)	$ (1.76)	$ (0.09)	$ (0.19)
Shares used in computing basic and diluted net loss per share	14,672,000			7,654,000			12,146,000	7,502,000	193,178,000	85,900,000

CONSOLIDATED STATEMENTS OF CONV

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Series A Convertible Preferred Stock	Total
Balance Beginning, Amount at Jan. 31, 2017	$ 68	$ 46,026	$ (44,638)	$ 1,515	$ 2,971
Balance Beginning, Shares at Jan. 31, 2017	67,719,577			1,515
Increase (decrease) in stockholders' deficit
Issuance of common stock, net of expenses	$ 57	15,992			16,049
Issuance of common stock, net of issuance costs (in shares)	57,185,258
Issuance of common stock due to exercise of options		10			10
Issuance of common stock due to exercise of options (in shares)	40,000
Issuance of common stock due to exercise of warrants	$ 31	613			644
Issuance of common stock due to exercise of warrants (in shares)	30,789,103
Conversion of Series A convertible preferred stock to common stock	$ 4	1,511		$ (1,515)
Conversion of Series A convertible preferred stock to common stock	4,328,571			(1,515)
Stock-based compensation expense		1,887			1,887
Fair value of modification of warrants		151			151
Net and comprehensive loss			(16,640)		(16,640)
Balance Ending, Amount at Jan. 31, 2018	$ 6	66,344	(61,278)		5,072
Balance Ending, Shares at Jan. 31, 2018	6,402,500
Increase (decrease) in stockholders' deficit
Cumulative-effect adjustment from adoption of new accounting pronouncement			2		2
Issuance of common stock due to exercise of options	$ 1				1
Issuance of common stock due to exercise of options (in shares)	406
Issuance of common stock due to exercise of warrants	$ 1	6,960			6,961
Issuance of common stock due to exercise of warrants (in shares)	1,257,843
Stock-based compensation expense		593			593
Net and comprehensive loss			(4,402)		(4,402)
Balance Ending, Amount at Apr. 30, 2018	$ 8	73,897	(65,678)		8,227
Balance Ending, Shares at Apr. 30, 2018	7,660,749
Balance Beginning, Amount at Jan. 31, 2018	$ 6	66,344	(61,278)		5,072
Balance Beginning, Shares at Jan. 31, 2018	6,402,500
Increase (decrease) in stockholders' deficit
Net and comprehensive loss					(13,202)
Balance Ending, Amount at Oct. 31, 2018	$ 8	75,061	(74,478)		591
Balance Ending, Shares at Oct. 31, 2018	7,665,945
Balance Beginning, Amount at Jan. 31, 2018	$ 6	66,344	(61,278)		5,072
Balance Beginning, Shares at Jan. 31, 2018	6,402,500
Increase (decrease) in stockholders' deficit
Cumulative-effect adjustment from adoption of new accounting pronouncement			2		2
Issuance of common stock due to exercise of options		1			1
Issuance of common stock due to exercise of options (in shares)	140,039
Issuance of common stock due to exercise of warrants	$ 58	10,488			10,546
Issuance of common stock due to exercise of warrants (in shares)	58,112,748
Stock-based compensation expense		2,061			2,061
Fair value of modification of warrants		874			874
Net and comprehensive loss			(17,258)		(17,258)
Balance Ending, Amount at Jan. 31, 2019	$ 9	79,823	(78,534)		1,298
Balance Ending, Shares at Jan. 31, 2019	8,732,612
Balance Beginning, Amount at Apr. 30, 2018	$ 8	73,897	(65,678)		8,227
Balance Beginning, Shares at Apr. 30, 2018	7,660,749
Increase (decrease) in stockholders' deficit
Issuance of common stock due to exercise of options (in shares)	222
Stock-based compensation expense		446			446
Net and comprehensive loss			(4,410)		(4,410)
Balance Ending, Amount at Jul. 31, 2018	$ 8	74,343	(70,088)		4,263
Balance Ending, Shares at Jul. 31, 2018	7,660,971
Increase (decrease) in stockholders' deficit
Issuance of common stock due to exercise of options (in shares)	4,974
Stock-based compensation expense		718			718
Net and comprehensive loss			(4,390)		(4,390)
Balance Ending, Amount at Oct. 31, 2018	$ 8	75,061	(74,478)		591
Balance Ending, Shares at Oct. 31, 2018	7,665,945
Balance Beginning, Amount at Jan. 31, 2019	$ 9	79,823	(78,534)		1,298
Balance Beginning, Shares at Jan. 31, 2019	8,732,612
Increase (decrease) in stockholders' deficit
Issuance of common stock, net of expenses	$ 1	3,553			3,554
Issuance of common stock, net of issuance costs (in shares)	1,745,800
Issuance of common stock due to exercise of options		4			4
Issuance of common stock due to exercise of options (in shares)	1,667
Stock-based compensation expense		191			191
Net and comprehensive loss			(3,623)		(3,623)
Balance Ending, Amount at Apr. 30, 2019	$ 10	83,571	(82,157)		1,424
Balance Ending, Shares at Apr. 30, 2019	10,480,079
Balance Beginning, Amount at Jan. 31, 2019	$ 9	79,823	(78,534)		1,298
Balance Beginning, Shares at Jan. 31, 2019	8,732,612
Increase (decrease) in stockholders' deficit
Net and comprehensive loss					(8,382)
Balance Ending, Amount at Oct. 31, 2019	$ 15	87,618	(86,916)		717
Balance Ending, Shares at Oct. 31, 2019	15,227,891
Balance Beginning, Amount at Apr. 30, 2019	$ 10	83,571	(82,157)		1,424
Balance Beginning, Shares at Apr. 30, 2019	10,480,079
Increase (decrease) in stockholders' deficit
Issuance of common stock, net of expenses	$ 4	3,253			3,257
Issuance of common stock, net of issuance costs (in shares)	3,707,504
Stock-based compensation expense		177			177
Net and comprehensive loss			(2,646)		(2,646)
Balance Ending, Amount at Jul. 31, 2019	$ 14	87,001	(84,803)		2,212
Balance Ending, Shares at Jul. 31, 2019	14,187,583
Increase (decrease) in stockholders' deficit
Issuance of common stock, net of expenses	$ 1	388			389
Issuance of common stock, net of issuance costs (in shares)	1,040,308
Stock-based compensation expense		229			229
Net and comprehensive loss			(2,113)		(2,113)
Balance Ending, Amount at Oct. 31, 2019	$ 15	$ 87,618	$ (86,916)		$ 717
Balance Ending, Shares at Oct. 31, 2019	15,227,891

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jul. 31, 2019	Apr. 30, 2019	Jan. 31, 2018
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Issuance costs	$ 200	$ 400	$ 1,907

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Cash flows from operating activities:
Net loss	$ (17,258)	$ (16,640)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,061	1,887
Fair value modification of warrants	874	151
Depreciation expense	62	52
Change in fair value of warrant liability	(28)	(364)
Other non-cash expense	3
Changes in assets and liabilities:
Prepaid expenses and other assets	(32)	75
Accounts payable	(13)	(1,175)
Accrued expenses and other liabilities	(661)	427
Net cash used in operating activities	(14,992)	(15,587)
Cash flows from investing activities:
Purchases of property and equipment	(43)	(41)
Net cash used in investing activities	(43)	(41)
Cash flows from financing activities:
Proceeds from the issuance of common stock, preferred stock and warrants, net of issuance costs		16,049
Proceeds from exercises of common stock warrants	10,546	644
Proceeds from exercises of stock options	1	10
Payments on capital lease obligation	(19)
Net cash provided by financing activities	10,528	16,703
Net increase (decrease) in cash and cash equivalents	(4,507)	1,075
Cash and cash equivalents as of beginning of period	7,576	6,501
Cash and cash equivalents as of end of period	3,069	7,576
Non-cash investing and financing activities:
Purchase of property and equipment through capital lease	61
Conversion of Series A convertible preferred stock to common stock		1,515
Supplemental disclosures:
Income taxes paid	$ 2	$ 2

DESCRIPTION OF BUSINESS AND SUM

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business BioPharmX Corporation (the Company) is incorporated under the laws of the state of Delaware and originally incorporated on August 30, 2010 in Nevada under the name Thompson Designs, Inc. The Company has one wholly-owned subsidiary, BioPharmX, Inc., a Nevada corporation. The Company is a specialty pharmaceutical company focused on the dermatology market. Its focus is to develop products that treat dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal. Its strategy is to bring new products to market by identifying optimal delivery mechanisms and/or alternative applications for United States Food and Drug Administration (FDA) approved or well characterized active pharmaceutical ingredients (APIs). The Company aims to reduce the time, cost and risks typically associated with new product development by utilizing APIs with demonstrated safety profiles and, when applicable, taking advantage of the regulatory approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Section 505(b)(2) permits an applicant for a new product, such as a new or improved formulation or a new use of an approved product, to rely in part on literature and/or the FDA’s findings of safety and/or effectiveness for a similar previously-approved product. The Company’s approach is to identify the limitations of current treatment options and work to develop novel products using its proprietary HyantX™ topical drug delivery system. Since the Company’s inception, substantially all of the Company’s efforts have been devoted to developing its product candidates, including conducting preclinical and clinical trials, and providing general and administrative support for its operations. The Company has financed its operations primarily through the sale of equity and convertible notes. Basis of Presentation and Principles of Consolidation These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended January 31, 2019, filed on March 14, 2019. The condensed consolidated balance sheet as of January 31, 2019, included herein, was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared on the same basis as the audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s statement of financial position as of October 31, 2019 and January 31, 2019, and the Company’s results of operations for the three and nine months ended October 31, 2019 and 2018 and cash flows for the nine months ended October 31, 2019 and 2018. The results for the three and nine months ended October 31, 2019 are not necessarily indicative of the results to be expected for the year ending January 31, 2020 or any future period. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates. Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation. Accounts receivable have been included in prepaid expenses and other current assets in the condensed consolidated balance sheets. The amount for the prior period has been reclassified to be consistent with the current year presentation and has no impact on previously reported total assets, total stockholders’ equity or net loss. Reverse Stock Split On April 25, 2019, the Company effected a 1-for-25 reverse stock split of its common stock. As a result of the reverse stock split, every twenty-five shares of the Company’s pre-reverse split outstanding common stock was combined and reclassified into one share of common stock. Par value per share remained unchanged at $0.001 per share. Proportionate voting rights and other rights of common stockholders were not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split; stockholders who would otherwise hold a fractional share of common stock received cash in an amount equal to the product obtained by multiplying (i) the closing price of the Company’s common stock on the last trading day prior to the effective date of the reverse stock split, by (ii) the number of shares of the Company’s common stock held by the stockholder that would otherwise have been exchanged for the fractional share interest. All stock options and warrants outstanding and common stock reserved for issuance under the Company’s equity incentive plans immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by 25 and, as applicable, multiplying the exercise price by 25, as a result of the reverse stock split. All of the share numbers, share prices and exercise prices have been adjusted on a retroactive basis as if such 1-for-25 reverse stock split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse stock split. Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not identify any impairment losses for either of the three or nine months ended October 31, 2019 or 2018. Net Loss per Share Basic net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock outstanding during the period. The weighted-average shares outstanding for the three and nine months ended October 31, 2019 and 2018 excludes 7,733 shares of unvested restricted common stock. Diluted net loss per share attributable to common stockholders is calculated based on the weighted-average number of shares of the Company’s common stock outstanding and other dilutive securities outstanding during the period. As of October 31, 2019 and 2018, approximately 6,325,000 and 7,604,000 of potentially dilutive securities, respectively, were excluded from the computation of diluted net loss per share because their effect on net loss per share would be anti-dilutive. Warrant Liability The Company accounts for certain of its warrants as derivative liabilities based on provisions relating to cash settlement options. The Company recorded a liability for the fair value of the warrants at the time of issuance, and at each reporting date the warrants are revalued to the instrument’s fair value. The fair value of the warrants are estimated using the Black-Scholes pricing model. This liability is subject to fair value re-measurement until the warrants are exercised or expired, and any change in fair value is recognized as other income or expense in the condensed consolidated statements of operations and comprehensive loss. Summary of Significant Accounting Policies These unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the fiscal year ended January 31, 2019. There have been no significant changes in the Company’s significant accounting policies for the three and nine months ended October 31, 2019, except for the adoption of Accounting Standards Update 2016-02, Leases , as discussed below, as compared to the significant accounting policies described in the Annual Report on Form 10-K for the fiscal year ended January 31, 2019. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, Leases , and in July 2018, ASU No. 2018-11, Targeted Improvements , which requires entities to recognize assets and liabilities for leases with lease terms greater than twelve months. The Company adopted this standard as of February 1, 2019, and the Company’s leases are classified as operating leases and will continue to be classified as operating leases under the new accounting method. Adoption of the new standard resulted in the recording of an operating lease right-to-use asset of $1.2 million, which represents the present value of the remaining lease payments as of the date of adoption discounted using an incremental borrowing rate of 15%, and an operating lease liability of $1.3 million. The adoption did not have an impact on the Company’s condensed consolidated statement of operations and comprehensive loss or cash flows. See Note 9 for further information. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting , which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The amendment is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company adopted this update as of February 1, 2019 and the adoption did not have a material effect on its condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , which amended certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendment is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting this amendment, but does not anticipate it will have a material impact on its disclosures. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.	1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business BioPharmX Corporation (the “Company”) is incorporated under the laws of the state of Delaware and originally incorporated on August 30, 2010 in Nevada under the name Thompson Designs, Inc. The Company has one wholly-owned subsidiary, BioPharmX, Inc., a Nevada corporation. The Company is a specialty pharmaceutical company focused on the dermatology market. Its focus is to develop products that treat dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal. Its strategy is to bring new products to market by identifying optimal delivery mechanisms and/or alternative applications for United States Food and Drug Adminstration (FDA) approved or well characterized active pharmaceutical ingredients, or APIs. The Company aims to reduce the time, cost and risks typically associated with new product development by utilizing APIs with demonstrated safety profiles and, when applicable, taking advantage of the regulatory approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Section 505(b)(2) permits an applicant for a new product, such as a new or improved formulation or a new use of an approved product, to rely in part on literature and/or the FDA’s findings of safety and/or effectiveness for a similar previously-approved product. The Company’s approach is to identify the limitations of current treatment options and work to develop novel products using our proprietary HyantX™ topical drug delivery system. The Company commercially launched its iodine breast health supplement, VI 2 OLET, in December 2014. In November 2018, the Company divested the rights to develop, manufacture, market and sell its molecular iodine technology, including VI 2 OLET. This divestiture resulted in a de minimis loss, which is included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. All tangible and intangible assets related to VI 2 OLET, including but not limited to existing customer and vendor arrangements, were included in this divestiture. Since the Company’s inception, substantially all of the Company’s efforts have been devoted to developing its product candidates, including conducting preclinical and clinical trials, and providing general and administrative support for its operations. The Company has financed its operations primarily through the sale of equity and convertible notes. Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates. Accounts Receivable, net Accounts receivable are related to the sale of the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Accounts receivable were recorded net of cash discounts for prompt payment and return allowances. The allowance for doubtful accounts receivable recorded as of January 31, 2019 and 2018 was immaterial. Inventories Inventories as of January 31, 2018 were related to the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Inventories were stated at the lower of cost or net realizable value. Cost was determined using the standard cost method which approximated actual cost on a first-in, first-out basis. The Company regularly reviewed inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for inventory, which may have become obsolete or are in excess of anticipated demand or net realizable value. Fair Value of Financial Instruments Carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to their short maturities. Property and Equipmen t , net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are as follows: Estimated Description Useful Life Furniture 5 - 7 Laboratory equipment 3 - 5 Computer and equipment 3 - 5 Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not identify any impairment losses for the years ended January 31, 2019 or 2018. Warrant Liability The Company accounts for certain of its warrants as derivative liabilities based on provisions relating to cash settlement options. The Company recorded a liability for the fair value of the warrants at the time of issuance, and at each reporting date the warrants are revalued to the instrument’s fair value. The fair value of the warrants are estimated using the Black-Scholes pricing model. This liability is subject to fair value re-measurement until the warrants are exercised or expired, and any change in fair value is recognized as other income or expense in the consolidated statements of operations and comprehensive loss. Revenue Recognition Revenue is related to the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Effective February 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method. The cumulative effect of the initial application of ASC 606 of approximately $2,000 was recognized as an adjustment to accumulated deficit and a decrease to deferred revenue as of February 1, 2018. The adoption of ASC 606 did not have a material impact on the Company’s consolidated balance sheet, statement of operations and comprehensive loss and statement of cash flows for the year ended January 31, 2019. Revenue is recognized when control is transferred to the customer, which is typically upon shipment. There are no significant post-shipment obligations. Revenue is recognized at the transaction price, which includes estimates of variable consideration for reserves related to estimated product returns, pricing discounts or other concessions. These estimates are based on estimates of the amount earned or to be claimed on the related sales and are based on historical information and current contractual requirements. The Company evaluated whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No such assets existed as of January 31, 2019 or February 1, 2018. As of February 1, 2018, deferred revenue was immaterial. The Company applies the practical expedient to make adjustments for a significant financing component unnecessary if, at contract inception, the Company does not expect the period between customer payment and transfer of control of the promised goods or services to the customer to exceed one year. During the year ended January 31, 2019, the Company did not have any contracts for the sale of its products with its customers with a significant financing component. The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. During the year ended January 31, 2019, the Company expensed the incremental costs of obtaining the contract as an expense when incurred as the amortization period was one year or less. Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Cost of Good Sold Cost of goods sold is related to the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Cost of good sold includes direct costs related to the sale of VI 2 OLET, write-downs of excess and obsolete inventories and amortization of intangible assets. Shipping and Handling Costs Shipping and handling costs are expensed as incurred and are included in cost of goods sold. Research and Development Expenses Research and development expenses are expensed as incurred and consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations, product development, consulting, materials, supplies, and facilities and other overhead allocations. Advertising Expenses The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were approximately $10,000 and $29,000 for the years ended January 31, 2019 and 2018, respectively. Income Taxes The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when management estimates, based on available objective evidence, that it is more likely than not that the benefit will not be realized for the deferred tax assets. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. No interest expense was recognized during the periods presented. Stock-Based Compensation The Company recognizes stock-based compensation for equity awards on a straight-line basis over their vesting periods based on the grant date fair value. The Company estimates the fair value of stock options granted using the Black-Scholes pricing model. This model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss is the change in equity of an enterprise, except those resulting from stockholder transactions. Accordingly, comprehensive loss includes certain changes in equity that are excluded from net loss. For the years ended January 31, 2019 and 2018, the Company’s comprehensive loss is equal to its net loss. There were no components of other comprehensive loss for any of the periods presented. Net Loss Per Share Basic net loss per share attributable to common stockholders is calculated based on the weighted average number of shares of the Company’s common stock outstanding during the period. The weighted average shares outstanding for the years ended January 31, 2019 and 2018 exclude 193,333 shares of unvested restricted common stock. Diluted net loss per share attributable to common stockholders is calculated based on the weighted average number of shares of the Company’s common stock outstanding and other dilutive securities outstanding during the period. As of January 31, 2019 and 2018, approximately 182,702,000 and 215,810,000, potentially dilutive securities, respectively, were excluded from the computation of diluted loss per share because their effect on net loss per share would be anti-dilutive. Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02, Leases , and in July 2018, ASU No. 2018-11, Targeted Improvements , which requires entities to recognize assets and liabilities for leases with lease terms greater than twelve months. The new guidance also requires quantitative and qualitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company does not expect a material impact on the statement of operations and comprehensive loss or cash flows from the adoption of this standard. In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting . This amendment impacts entities that change the terms or conditions of a share-based payment award. The Company adopted this guidance as of February 1, 2018 for awards that are modified after that date, and the adoption did not have a material effect on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting , which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The amendment is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated financial statements as a result of future adoption.

GOING CONCERN

GOING CONCERN	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
GOING CONCERN
GOING CONCERN	2. GOING CONCERN The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and will continue to conduct operations for the foreseeable future and realize assets and discharge liabilities in the ordinary course of operations. As of October 31, 2019, the Company had cash and cash equivalents of $1.4 million and working capital of $0.3 million. The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock and the issuance of convertible notes. The Company incurred a net loss of $2.1 million and $4.4 million for the three months ended October 31, 2019 and 2018, respectively, and a net loss of $8.4 million and $13.2 million for the nine months ended October 31, 2019 and 2018, respectively. The Company had an accumulated deficit of $86.9 million as of October 31, 2019. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company has taken steps to reduce its cash outflow by reducing headcount and curtailing certain research and development activities. The Company has retained a transaction advisory firm to assist with the evaluation of strategic alternatives. Strategic alternatives that have been or are being considered include a license or sale of late-stage topical minocycline product candidates, a sale of the Company, a strategic business combination and raising additional capital. However, there can be no assurance that the strategic review process will result in any transaction or on terms which are favorable to the Company. Failure to enter into a strategic transaction or raise additional capital could have a material adverse effect on the Company’s ability to achieve its business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.	2. GOING CONCERN The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern and will continue to conduct operations for the foreseeable future and realize assets and discharge liabilities in the ordinary course of operations. As of January 31, 2019, the Company had cash and cash equivalents of $3.1 million and working capital of $1.1 million. The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock and the issuance of convertible notes. The Company incurred a net loss of $17.3 million and $16.6 million for the years ended January 31, 2019 and 2018, respectively, and had an accumulated deficit of $78.5 million as of January 31, 2019. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company continues its research and development efforts for its product candidates, which will require significant funding. If the Company is unable to obtain additional financing in the future or research and development efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses and either entering into a strategic partnership or raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available or on terms which are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, enter into a strategic partnership or reduce certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.

BALANCE SHEET DETAILS

BALANCE SHEET DETAILS	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
BALANCE SHEET DETAILS
BALANCE SHEET DETAILS	4. BALANCE SHEET DETAILS October 31, January 31, 2019 2019 (in thousands) Accrued expenses and other current liabilities: Compensation $ 417 $ 371 Operating lease liability - current portion 260 — Research and development 119 399 Other 67 164 $ 863 $ 934	3. BALANCE SHEET DETAILS January 31, 2019 2018 (in thousands) Inventories: Work in process $ — $ Finished goods — Channel inventory — $ — $ 10 January 31, 2019 2018 (in thousands) Property and equipment, net: Furniture $ — $ Laboratory equipment Computer and equipment Less: accumulated depreciation $ 148 $ 109 Depreciation expense for the years ended January 31, 2019 and 2018 was approximately $62,000 and $52,000, respectively. January 31, 2019 2018 (in thousands) Accrued liabilities: Research and development $ 399 $ 404 Payroll 371 368 Legal 45 438 Purchase commitment liability — 215 Deferred revenue — 8 Other 119 170 $ 934 $ 1,603

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	3. FAIR VALUE MEASUREMENTS The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. · Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. · Level 2— Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. · Level 3— Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. As of October 31, 2019 and January 31, 2019, the Company held $1.3 million and $2.5 million, respectively, in money market funds, which are classified as Level 1 within the fair value hierarchy. No unrealized gains or losses are recorded in connection with these amounts. The fair value of the warrant liability was classified as a Level 3 liability, as the Company uses unobservable inputs to value it. The table below presents the activity within Level 3 of the fair value hierarchy (in thousands): Warrant Liability Balance as of February 1, 2019 $ 11 Change in fair value of warrants (9) Balance as of April 30, 2019 2 Change in fair value of warrants (2) Balance as of July 31, 2019 and October 31, 2019 $ — The warrant liability is included in long - term liabilities on the condensed consolidated balance sheets.	4. FAIR VALUE MEASURMENTS The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. · Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. · Level 2— Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. · Le vel 3— Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. As of January 31, 2019 and 2018, the Company held $2.5 million and $7.1 million, respectively, in money market funds, which are classified as Level 1 within the fair value hierarchy. No unrealized gains or losses are recorded in connection with these amounts. The fair value of the warrant liability was classified as a Level 3 liability, as the Company uses unobservable inputs to value it. The table below presents the activity within Level 3 of the fair value hierarchy (in thousands): Warrant Liability Balance as of January 31, 2017 $ 403 Change in fair value of warrants (364) Balance as of January 31, 2018 39 Change in fair value of warrants (28) Balance as of January 31, 2019 $ 11 The warrant liability is included in long - term liabilities on the consolidated balance sheets.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	5. COMMITMENTS AND CONTINGENCIES Commitments The Company is party to an agreement with a contract research organization (CRO) to conduct the Phase 2 clinical trial for BPX04, a topical antibiotic for the treatment of rosacea. The actual amounts owed under the agreement and the timing of those obligations depend on various factors, including the rate of patient enrollment, any protocol amendments and other factors relating to the clinical trial. As of October 31, 2019, all liability amounts were recorded, excluding any potential amendments to the agreement. The Company can terminate the agreement at any time and any amounts incurred through the termination date would be due to the CRO. See Note 9 for discussion regarding the Company’s operating and financing lease commitments. Legal Proceedings The Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patents or other intellectual property rights. The Company is not a party to any material legal proceeding, nor is it aware of any pending or threatened litigation that the Company believes is likely to have a material adverse effect on its business, results of operations, cash flows or financial condition should such litigation be resolved unfavorably. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts. Indemnification The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has entered into indemnification agreements with its directors, officers and certain of its medical advisors that may require the Company to indemnify its directors, officers and such medical advisors against liabilities that may arise by reason of their status or service in these roles, other than liabilities arising from willful misconduct of the individual. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such indemnifications has been recorded to date.	5. COMMITMENTS AND CONTINGENCIES Commitments The following table summarizes the Company’s commitments as of January 31, 2019 (in thousands): Fiscal years ending January 31, Total 2020 2021 2022 2023 2024 Operating lease $ 1,539 $ 280 $ 315 $ 324 $ 334 $ 286 Capital lease for laboratory equipment 47 22 22 3 — — Total $ 1,586 $ 302 $ 337 $ 327 $ 334 $ 286 On October 30, 2018, the Company signed a lease for 11,793 square feet of office and laboratory space in San Jose, California. The lease commenced in December 2018 and will terminate in December 2023. Rent expense for the years ended January 31, 2019 and 2018 was approximately $586,000 and $612,000, respectively. The Company is party to an agreement with a contract research organization (CRO) to conduct the Phase 2 clinical trial for BPX04, a topical antibiotic for the treatment of rosacea. The actual amounts owed under the agreement and the timing of those obligations depend on various factors, including the rate of patient enrollment, any protocol amendments and other factors relating to the clinical trial. As of January 31, 2019, the remaining liability under the agreement, excluding any potential amendments to the agreement, was $0.8 million. The Company can terminate the agreement at any time and any amounts incurred through the termination date would be due to the CRO. The Company recorded a capital lease obligation related to laboratory equipment in March 2018. The leased asset value was approximately $61,000 and the corresponding current and long-term liabilities were recorded in accrued liabilities and other current liabilities and long-term liabilities, respectively. Total future payments representing interest until the termination of lease are approximately $5,000. Legal Proceedings The Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patents or other intellectual property rights. The Company is not a party to any material legal proceeding, nor is it aware of any pending or threatened litigation that the Company believes is likely to have a material adverse effect on its business, results of operations, cash flows or financial condition should such litigation be resolved unfavorably. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts. Indemnification The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has entered into indemnification agreements with its directors, officers and certain of its medical advisors that may require the Company to indemnify its directors, officers and such medical advisors against liabilities that may arise by reason of their status or service in these roles, other than liabilities arising from willful misconduct of the individual. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such indemnifications has been recorded to date.

CONVERTIBLE PREFERRED STOCK AND

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
STOCKHOLDERS’ EQUITY
CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY	6. STOCKHOLDERS’ EQUITY Common Stock In March 2019, the Company issued 1,745,800 shares of common stock at a price per share of $0.09 resulting in net proceeds of $3.6 million in a registered direct offering. In May 2019, the Company entered into a Capital on Demand TM Sales Agreement (Sales Agreement) with JonesTrading Institutional Services LLC, as agent (JonesTrading), pursuant to which the Company may offer and sell, from time to time through JonesTrading, shares of the Company’s common stock, par value $0.001 per share (the Common Stock), having an aggregate offering price of up to $8.5 million. As of October 31, 2019, the Company had sold an aggregate of 4,747,812 shares of Common Stock pursuant to the terms of such Sales Agreement for aggregate net proceeds of $3.6 million. Warrants A summary of warrants outstanding as of October 31, 2019 is as follows: Total Price per Share Expiration Date Warrants related to November 2014 financing 19,762 $ 92.50 November 2019 Warrants related to June 2015 financing 4,363 $ 68.75 June 2020 Warrants related to April 2016 financing 70,581 $ 30.00 April 2021 Warrants related to September 2016 financing (1) 51,466 $ 18.75 September 2021 to March 2022 Warrants related to November 2016 financing 1,216,230 $ 8.75 November 2024 Warrants related to November 2016 financing 35,818 $10.938 November 2022 Warrants related to November 2016 financing 7,926 $ 8.25 November 2022 Warrants related to April 2017 financing 32,053 $ 22.50 October 2022 Warrants related to October 2017 financing 153,848 $ 7.50 October 2022 Warrants related to November 2017 financing 2,277,412 $ 5.00 November 2022 Warrants related to November 2018 financing (2) 1,066,670 $ 4.10 May/June 2021 4,936,129 (1) In connection with the sale of common stock in September 2016, warrants to purchase 51,466 shares of common stock were issued at an exercise price of $18.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of October 31, 2019, the fair value of the warrant liability was immaterial and was included in other long-term liabilities. (2) On November 20, 2018, the Company entered into agreements with holders of certain of its warrants to purchase common stock with an exercise price per share of $6.25 originally issued on November 24, 2017 (Existing Warrants), whereby the holders and the Company agreed that the holders would cash exercise up to 1,066,670 shares of common stock underlying such Existing Warrants at a reduced price of $3.50, and the Company would issue new warrants to such holders to purchase up to an aggregate of 1,066,670 shares of common stock (New Warrants). The New Warrants are exercisable after the six-month anniversary of their issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $4.10. The Company recorded a charge for the incremental fair value of approximately $874,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.51%, contractual term of 6 months, expected volatility of 78.4% and a dividend rate of 0%. Equity Incentive Plan On July 5, 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan), which permits the Company to grant equity awards to directors, officers, employees and consultants. In connection with the adoption of the 2016 Plan, the Company ceased to grant equity awards under its 2014 Equity Incentive Plan (2014 Plan), which was adopted on January 23, 2014. All grants and awards under the 2014 Plan, including stock options previously issued under BioPharmX, Inc.’s 2011 Equity Incentive Plan that were substituted with stock options issued under the 2014 Plan, remain in effect in accordance with their terms. Stock options generally vest in one to four years and expire ten years from the date of grant. In March 2017, the 2016 Plan was amended and the shares reserved for issuance were increased by 800,000 shares to a total of 960,000 shares of common stock. In August 2018, the 2016 Plan was amended and the shares reserved for issuance were increased by 2,000,000 shares to a total of 2,960,000 shares of common stock. The 2014 Plan and 2016 Plan are referred to collectively as the “Plans.” The following table summarizes the Company’s stock option awards under the Plans: Weighted Average Remaining Aggregate Available for Exercise Contractual Intrinsic Grant Shares Prices Life Value (in thousands) Balance as of February 1, 2019 2,107,575 917,945 $ $ 23 Granted (16,720) 16,720 $ 3.21 Exercised — (1,667) $ 2.50 Canceled and expired under the 2014 Plan — $ 28.27 Canceled under the 2016 Plan 69,180 (69,180) $ 8.84 Balance as of April 30, 2019 2,160,035 $ 8.27 8.35 $ — Granted (877,100) $ 0.80 Canceled and expired under the 2014 Plan — $ 13.06 Canceled under the 2016 Plan 224,654 (224,654) $ 4.18 Balance as of July 31, 2019 1,507,589 $ 4.44 8.62 $ — Canceled and expired under the 2014 Plan — $ 28.13 Canceled under the 2016 Plan $ 8.54 Balance as of October 31, 2019 $ 3.93 8.95 $ — Vested and exercisable $ 7.56 8.05 $ — Vested and expected to vest $ 4.26 8.87 $ — Inducement Grants The Company has also awarded inducement option grants to purchase common stock to new employees outside of the 2016 Plan as permitted under Section 711(a) of the NYSE American Company Guide. Such options vest at the rate of 25% of the shares on the first anniversary of the commencement of such employee’s employment with the Company, and then one forty-eighth (1/48) of the shares monthly thereafter subject to such employee’s continued service. The following table summarizes the Company’s inducement grant stock option awards: Weighted Average Remaining Exercise Contractual Aggregate Shares Prices Life Intrinsic Value (in thousands) Balance as of February 1, 2019 31,000 $ $ — Canceled (6,000) $ Balance as of April 30, 2019 25,000 $ $ — Canceled (750) $ Balance as of July 31, 2019 24,250 $ $ — Canceled (8,250) $ Balance as of October 31, 2019 16,000 $ $ — Vested and exercisable 6,667 $ $ — Vested and expected to vest 13,819 $ $ — The following table summarizes significant ranges of outstanding and exercisable options as of October 31, 2019: Options Outstanding Options Vested and Exercisable Weighted Average Weighted Weighted Remaining Average Number Average Number Contractual Exercise Vested and Exercise Range of Exercise Prices Outstanding Life (in Years) Prices Exercisable Prices $0.44 - $0.84 $ $ $0.85 - $4.00 $ $ $4.01 - $10.50 $ $ $10.51- $18.50 $ $ $18.51 - $28.50 $ $ $28.51 - $75.00 $ 14,354 $ 51.19 $ $ There were no stock options exercised during the three months ended October 31, 2019. The total intrinsic value of stock options exercised was less than $1,000 during the nine months ended October 31, 2019. The total intrinsic value of stock options exercised during the three and nine months ended October 31, 2018 was approximately $24,000 and $26,000, respectively.	6. CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY Common Stock In April 2017, the Company issued 6,410,258 shares of common stock at a price per share of $0.78 resulting in net proceeds of $4.4 million and warrants to purchase 3,365,385 shares of common stock at an exercise price of $0.90 in a registered direct offering. In July 2017, the Company issued 5,500,000 shares of common stock at a price per share of $0.36 resulting in net proceeds of $1.9 million in a registered direct offering. In November 2017, the Company issued 45,275,000 shares of common stock, pre-funded warrants to purchase 28,225,000 shares of common stock, and accompanying Series A common warrants to purchase 73,500,000 shares of common stock (“Series A Warrants”), and accompanying Series B common warrants to purchase 73,500,000 shares of common stock (“Series B Warrants”), resulting in net proceeds of $9.7 million. Each share of common stock and pre-funded warrant was sold together with a Series A Warrant to purchase one share of common stock and a Series B Warrant to purchase one share of common stock. The public offering price was $0.15 per share of common stock and accompanying Series A Warrant and Series B Warrant and $0.1490 per pre-funded warrant and accompanying Series A Warrant and Series B Warrant. The pre-funded warrants were issued and sold to purchasers in lieu of shares of common stock that would otherwise result in the purchaser's beneficial ownership exceeding 4.99% (or at the election of the purchaser, 9.99%) of the Company’s outstanding Common Stock immediately following the closing of the offering. The pre-funded warrants have a nominal exercise price of $0.001 per share and have been fully exercised. The Series A Warrants have an exercise price of $0.20 per share, are exercisable immediately and expire five years from the date of issuance. The Series B Warrants have an exercise price of $0.25 per share, are exercisable immediately and expire on the earlier of (1) the twenty-first trading day after the Company issues a press release announcing it has entered into a strategic licensing, collaboration, partnership or similar agreement for the commitment to fund its Phase 3 trials for BPX01, and (2) the eighteen month anniversary of issuance. Series A Convertible Preferred Stock Pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on November 22, 2016, 10,000 shares of Series A convertible preferred stock were designated. In November 2016, the Company issued 1,515 shares of Series A convertible preferred stock (Preferred Stock), which included warrants to purchase 3,246,429 shares of common stock. The Preferred Stock had a purchase price of $1,000 per share and was convertible into common stock at a conversion rate of $0.35 per share. The Preferred Stock contained a beneficial conversion feature valued at $0.1 million, which was recorded as a deemed dividend at the time of issuance, which was considered to be the earliest time of conversion. In January 2018, the Preferred Stock was converted into 4,328,571 shares of common stock. Pursuant to the Certificate of Elimination filed with the Secretary of State of the State of Delaware on March 6, 2018, all shares of Series A convertible preferred stock previously designated were returned to the status of authorized but unissued shares of preferred stock, without designation as to series or rights, preferences, privileges or limitations. Warrants A summary of warrants outstanding as of January 31, 2019 is as follows: Total Price per Share Expiration Date Warrants related to January 2014 agreement 289,505 $ 1.85 May 2019 Warrants related to May 2014 agreement 316,395 $2.035 May 2019 Warrants related to April to November 2014 financing 1,661,055 $ 3.70 April 2019 - November 2019 Warrants related to June 2015 financing 109,091 $ 2.75 June 2020 Warrants related to April 2016 financing 1,952,000 $ 1.20 April 2021 Warrants related to September 2016 financing (1) 1,286,501 $ 0.75 September 2021 to March 2022 Warrants related to November 2016 financing 30,406,061 $ 0.35 November 2022 to November 2024 Warrants related to November 2016 financing 895,450 $ 0.44 November 2022 Warrants related to November 2016 financing 198,214 $ 0.33 November 2022 Warrants related to April 2017 financing 801,282 $ 0.90 October 2022 Warrants related to October 2017 financing (2) 3,846,152 $ 0.30 October 2022 Warrants related to November 2017 financing 56,935,191 $ 0.20 November 2022 Warrants related to November 2017 financing (3) 33,422,061 $ 0.25 May 2019 Warrants related to November 2018 financing (3) 26,666,666 $0.164 May/June 2021 (1) In connection with the sale of common stock in September 2016, warrants to purchase 1,286,501 shares of common stock were issued at an exercise price of $0.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of January 31, 2019, the fair value of the warrant liability was approximately $11,000 and was included as a long-term liability. (2) On October 23, 2017, the Company entered into agreements with certain of these warrant holders to permit their immediate exercise of 2,564,103 shares of common stock underlying the warrants at an exercise price per share of $0.24. The Company recorded a charge for the incremental fair value of approximately $151,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.03%, contractual term of 5 years, expected volatility of 83.9% and a dividend rate of 0%. In addition, these warrant holders were issued new warrants to purchase up to an aggregate of 3,846,152 shares of common stock at an exercise price per share of $0.30. (3) On November 20, 2018, the Company entered into agreements with holders of certain of its warrants to purchase common stock with an exercise price per share of $0.25 originally issued on November 24, 2017 (Existing Warrants), whereby the holders and the Company agreed that the holders would cash exercise 26,666,666 shares of common stock underlying such Existing Warrants at a reduced price of $0.14, and the Company would issue new warrants to such holders to purchase up to an aggregate of 26,666,666 shares of common stock (New Warrants). The New Warrants are exercisable after the six-month anniversary of their issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $0.164. The Company recorded a charge for the incremental fair value of approximately $874,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.51%, contractual term of 6 months, expected volatility of 78.4% and a dividend rate of 0%. Equity Incentive Plan On July 5, 2016, the Company adopted the 2016 Equity Incentive Plan (“2016 Plan”), which permits the Company to grant equity awards to directors, officers, employees and consultants. In connection with the adoption of the 2016 Plan, the Company ceased to grant equity awards under its 2014 Equity Incentive Plan (“2014 Plan”), which was adopted on January 23, 2014. All grants and awards under the 2014 Plan, including stock options previously issued under BioPharmX, Inc.’s 2011 Equity Incentive Plan that were substituted with stock options issued under the 2014 Plan, remain in effect in accordance with their terms. Stock options generally vest in one to four years and expire ten years from the date of grant. In March 2017, the 2016 Plan was amended and the shares reserved for issuance was increased by 20,000,000 shares to a total of 24,000,000 shares. In August 2018, the 2016 Plan was amended and the shares reserved for issuance were increased by 50,000,000 shares to a total of 74,000,000 shares of common stock. The 2014 Plan and 2016 Plan are referred to collectively as the “Plans.” The following table summarizes the Company’s stock option activities under the Plans: Weighted Average Remaining Aggregate Available for Exercise Contractual Intrinsic Grant Shares Prices Life Value (in thousands) Balance as of February 1, 2017 252,379 6,465,829 $ $ 238 Shares authorized for issuance 20,000,000 — Granted (18,553,000) 18,553,000 $ Exercised — (40,000) $ Canceled and returned to the 2016 Plan 185,499 (185,499) $ Canceled subsequent to termination of the 2014 Plan — (68,667) $ Balance as of January 31, 2018 1,884,878 24,724,663 $ $ 304 Shares authorized for issuance 50,000,000 — Granted (10,444,000) 10,444,000 $ Exercised — (278,196) $ Canceled and returned to the 2016 Plan 11,262,538 (11,262,538) $ Canceled subsequent to termination of the 2014 Plan — (680,060) $ Balance as of January 31, 2019 52,703,416 22,947,869 $ $ 23 Vested and exercisable 9,257,545 $ $ 13 Vested and expected to vest 21,836,056 $ $ 22 Inducement Grants The Company has also awarded inducement option grants to purchase common stock to new employees outside of the 2016 Plan as permitted under Section 711(a) of the NYSE American Company Guide. Such options vest at the rate of 25% of the shares on the first anniversary of the commencement of such employee’s employment with the Company, and then one forty-eighth (1/48) of the shares monthly thereafter subject to such employee’s continued service. The following table summarizes the Company’s inducement grant stock option activities: Weighted Average Remaining Exercise Contractual Aggregate Shares Prices Life Intrinsic Value (in thousands) Balance as of February 1, 2017 and 2018 660,000 $ $ — Granted 400,000 $ Canceled (285,000) $ Balance as of January 31, 2019 775,000 $ $ — Vested and exercisable 332,812 $ $ — Vested and expected to vest 747,437 $ $ — The following table summarizes significant ranges of outstanding and exercisable options as of January 31, 2019: Options Outstanding Options Vested and Exercisable Weighted Average Weighted Weighted Remaining Average Number Average Number Contractual Exercise Vested and Exercise Range of Exercise Prices Outstanding Life (in Years) Prices Exercisable Prices $0.10 - $0.16 $ $ $0.17 - $0.35 $ $ $0.36 - $0.65 $ $ $0.66 - $1.14 $ $ $1.15 - $3.00 $ 1,003,748 $ 1.80 $ $ The total intrinsic value of stock options exercised during the years ended January 31, 2019 and 2018 was approximately $26,000 and $4,000, respectively. During the year ended January 31, 2019, certain stock options were exercised pursuant to net exercise provisions, resulting in 138,157 shares of common stock retired in exchange of the total exercise price. The weighted average grant date fair values of the stock options granted during the years ended January 31, 2019 and 2018 was $0.12 and $0.21, respectively.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION	7. STOCK-BASED COMPENSATION The following table summarizes the stock-based compensation expenses included in the condensed consolidated statement of operations and comprehensive loss (in thousands): For the three months ended For the nine months ended October 31, October 31, 2019 2018 2019 2018 Research and development $ 30 $ 166 $ 218 $ 525 Sales and marketing 12 114 45 355 General and administrative 187 438 334 877 Total $ 229 $ 718 $ 597 $ 1,757 The Company estimates the fair value of stock options granted using the Black-Scholes pricing model. This model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. For employee grants, the fair value is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. As of October 31, 2019, total compensation costs related to unvested, but not yet recognized, stock-based awards was $1.0 million, net of estimated forfeitures. This cost will be amortized on a straight-line basis over a weighted average remaining period of 2.3 years and will be adjusted for subsequent changes in estimated forfeitures. Valuation Assumptions There were no stock options granted during the three months ended October 31, 2019. During the nine months ended October 31, 2019, the weighted average grant date fair value of stock options granted was $0.44 per share. The following assumptions were used to calculate the estimated fair value of awards granted for the periods ended: For the three months ended For the nine months ended October 31, October 31, 2019 2018 2019 2018 Expected volatility — 78.8% - 91.0% 68.3% - 70.8% 78.8% - 91.0% Expected term in years — 4.0 - 8.6 4.0 - 8.6 Risk-free interest rate — 2.72% - 3.10% 1.88% - 2.51% 2.72% - 3.10% Expected dividend yield — — — — Expected Term The expected term represents the period that the Company’s stock-based awards are expected to be outstanding. For awards granted subject only to service vesting requirements, the Company utilizes the simplified method for estimating the expected term of the stock-based award, instead of historical exercise data. Expected Volatility The Company uses the historical volatility of the price of shares of common stock of selected public companies, including the Company’s stock price, in the biotechnology sector due to its limited trading history. Risk-Free Interest Rate The Company bases the risk-free interest rate used in the Black-Scholes pricing model upon the implied yield curve currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term used as the assumption in the model. Expected Dividend The Company has never paid dividends on its shares of common stock and currently does not intend to do so and, accordingly, the dividend yield percentage is zero for all periods.	7. STOCK-BASED COMPENSATION The following table summarizes the stock-based compensation expenses included in the statements of operations and comprehensive loss (in thousands): Year ended January 31, 2019 2018 Research and development $ 654 $ 545 Sales and marketing 414 393 General and administrative 993 949 Total $ 2,061 $ 1,887 The Company estimates the fair value of stock options granted using the Black-Scholes pricing model. This model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. For employee grants, the fair value is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. As of January 31, 2019, total compensation costs related to unvested, but not yet recognized, stock-based awards was $2.0 million, net of estimated forfeitures. This cost will be amortized on a straight-line basis over a weighted average remaining period of 2.72 years and will be adjusted for subsequent changes in estimated forfeitures. Valuation Assumptions The following assumptions were used to calculate the estimated fair value of awards granted: Year ended January 31, 2019 2018 Expected volatility 78.8% - 91.0% 83.9% - 96.8% Expected term in years 4.0 6.0 - 9.39 Risk-free interest rate 2.43% - 2.98% 1.80% - 2.70% Expected dividend yield — — Expected Term The expected term represents the period that the Company’s stock-based awards are expected to be outstanding. For awards granted subject only to service vesting requirements, the Company utilizes the simplified method for estimating the expected term of the stock-based award, instead of historical exercise data. Expected Volatility The Company uses the historical volatility of the price of shares of common stock of selected public companies, including the Company’s stock price, in the biotechnology sector due to its limited trading history. Risk-Free Interest Rate The Company bases the risk-free interest rate used in the Black-Scholes pricing model upon the implied yield curve currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term used as the assumption in the model. Expected Dividend The Company has never paid dividends on its common shares and currently does not intend to do so and, accordingly, the dividend yield percentage is zero for all periods.

EMPLOYEE BENEFIT PLAN

EMPLOYEE BENEFIT PLAN	12 Months Ended
	Jan. 31, 2019
EMPLOYEE BENEFIT PLAN
EMPLOYEE BENEFIT PLAN	8. EMPLOYEE BENEFIT PLAN The Company sponsors a 401(k) defined contribution plan for its employees. This plan provides for tax-deferred salary deductions for all full-time employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to this plan, as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company may match employee contributions in amounts to be determined at the Company’s sole discretion. The Company has made no contributions to the plan for the years ended January 31, 2019 and 2018.

INCOME TAXES

INCOME TAXES	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
INCOME TAXES
INCOME TAXES	8. INCOME TAXES The Company evaluates its ability to recover deferred tax assets, in full or in part, by considering all available positive and negative evidence, including past operating results and its forecast of future taxable income on a jurisdictional basis. The Company bases its estimate of current and deferred taxes on the tax laws and rates that are currently in effect in the appropriate jurisdiction. Changes in laws or rates may affect the tax provision as well as the amount of deferred tax assets or liabilities. Current tax laws impose substantial restrictions on the utilization of net operating loss and credit carry-forwards in the event of an “ownership change,” as defined by the Internal Revenue Code. If there should be an ownership change, the Company’s ability to utilize its carry-forwards could be limited. As of October 31, 2019 and January 31, 2019, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions. The 2010 to 2019 tax years remain open for examination by the federal and state authorities.	9. INCOME TAXES No federal income taxes were paid during the years ended January 31, 2019 and 2018 due to the Company’s net losses. The provision of income taxes consist of state minimum income taxes. As of January 31, 2019, the Company had available federal net operating loss (“NOL”) carryforwards of approximately $68.6 million which will begin to expire in 2030 and California state NOL carryforwards of approximately $62.4 million which will begin to expire in 2033. As of January 31, 2019 and 2018, the net deferred tax assets of approximately $21.1 million and $16.3 million, respectively, generated primarily by NOL carryforwards, have been fully reserved due to the uncertainty surrounding the realization of such benefits. The net valuation allowance increased by approximately $4.9 million and $1.0 million during the years ended January 31, 2019 and 2018, respectively. Current tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an “ownership change,” as defined by the Internal Revenue Code. If there should be an ownership change, the Company’s ability to utilize its carryforwards could be limited. Significant components of the Company’s deferred tax assets were as follows (in thousands): January 31, Deferred tax assets: 2019 2018 Net operating loss carryforwards $ 18,769 $ 14,314 Stock-based compensation expense 1,163 831 Tax credit carryforwards 1,022 735 Other 160 377 Total deferred tax assets 21,114 16,257 Less: valuation allowance (21,114) (16,257) Net deferred tax assets $ — $ — A reconciliation of income taxes provided at the federal statutory rate (21% in 2019) to the actual income tax provision was as follows (in thousands): Year ended January 31, 2019 2018 Income tax benefit computed at U.S. statutory rate $ (3,624) $ (5,477) State income tax (net of federal benefit) (1,478) (1,150) Change in federal rate from 34% to 21% — 7,662 Change in valuation allowance 4,857 (1,039) Research and development credits (158) (129) Other 405 135 Provision for income taxes $ 2 $ 2 As of January 31, 2019 and 2018, the Company did not have any material unrecognized tax benefits. The tax years from 2010 to 2019 remain open for examination by the federal and state authorities.

DESCRIPTION OF BUSINESS AND S_2

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended January 31, 2019, filed on March 14, 2019. The condensed consolidated balance sheet as of January 31, 2019, included herein, was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared on the same basis as the audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s statement of financial position as of October 31, 2019 and January 31, 2019, and the Company’s results of operations for the three and nine months ended October 31, 2019 and 2018 and cash flows for the nine months ended October 31, 2019 and 2018. The results for the three and nine months ended October 31, 2019 are not necessarily indicative of the results to be expected for the year ending January 31, 2020 or any future period.	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.
Accounts Receivable		Accounts Receivable, net Accounts receivable are related to the sale of the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Accounts receivable were recorded net of cash discounts for prompt payment and return allowances. The allowance for doubtful accounts receivable recorded as of January 31, 2019 and 2018 was immaterial.
Inventories		Inventories Inventories as of January 31, 2018 were related to the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Inventories were stated at the lower of cost or net realizable value. Cost was determined using the standard cost method which approximated actual cost on a first-in, first-out basis. The Company regularly reviewed inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for inventory, which may have become obsolete or are in excess of anticipated demand or net realizable value.
Fair Value of Financial Instruments		Fair Value of Financial Instruments Carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to their short maturities.
Property and Equipment, net		Property and Equipmen t , net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are as follows: Estimated Description Useful Life Furniture 5 - 7 Laboratory equipment 3 - 5 Computer and equipment 3 - 5
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not identify any impairment losses for either of the three or nine months ended October 31, 2019 or 2018.	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not identify any impairment losses for the years ended January 31, 2019 or 2018.
Warrant Liability	Warrant Liability The Company accounts for certain of its warrants as derivative liabilities based on provisions relating to cash settlement options. The Company recorded a liability for the fair value of the warrants at the time of issuance, and at each reporting date the warrants are revalued to the instrument’s fair value. The fair value of the warrants are estimated using the Black-Scholes pricing model. This liability is subject to fair value re-measurement until the warrants are exercised or expired, and any change in fair value is recognized as other income or expense in the condensed consolidated statements of operations and comprehensive loss.	Warrant Liability The Company accounts for certain of its warrants as derivative liabilities based on provisions relating to cash settlement options. The Company recorded a liability for the fair value of the warrants at the time of issuance, and at each reporting date the warrants are revalued to the instrument’s fair value. The fair value of the warrants are estimated using the Black-Scholes pricing model. This liability is subject to fair value re-measurement until the warrants are exercised or expired, and any change in fair value is recognized as other income or expense in the consolidated statements of operations and comprehensive loss.
Revenue Recognition		Revenue Recognition Revenue is related to the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Effective February 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method. The cumulative effect of the initial application of ASC 606 of approximately $2,000 was recognized as an adjustment to accumulated deficit and a decrease to deferred revenue as of February 1, 2018. The adoption of ASC 606 did not have a material impact on the Company’s consolidated balance sheet, statement of operations and comprehensive loss and statement of cash flows for the year ended January 31, 2019. Revenue is recognized when control is transferred to the customer, which is typically upon shipment. There are no significant post-shipment obligations. Revenue is recognized at the transaction price, which includes estimates of variable consideration for reserves related to estimated product returns, pricing discounts or other concessions. These estimates are based on estimates of the amount earned or to be claimed on the related sales and are based on historical information and current contractual requirements. The Company evaluated whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No such assets existed as of January 31, 2019 or February 1, 2018. As of February 1, 2018, deferred revenue was immaterial. The Company applies the practical expedient to make adjustments for a significant financing component unnecessary if, at contract inception, the Company does not expect the period between customer payment and transfer of control of the promised goods or services to the customer to exceed one year. During the year ended January 31, 2019, the Company did not have any contracts for the sale of its products with its customers with a significant financing component. The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. During the year ended January 31, 2019, the Company expensed the incremental costs of obtaining the contract as an expense when incurred as the amortization period was one year or less. Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue.
Cost of Good Sold		Cost of Good Sold Cost of goods sold is related to the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Cost of good sold includes direct costs related to the sale of VI 2 OLET, write-downs of excess and obsolete inventories and amortization of intangible assets.
Shipping and Handling Costs		Shipping and Handling Costs Shipping and handling costs are expensed as incurred and are included in cost of goods sold.
Research and Development Expenses		Research and Development Expenses Research and development expenses are expensed as incurred and consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations, product development, consulting, materials, supplies, and facilities and other overhead allocations.
Advertising Expenses		Advertising Expenses The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were approximately $10,000 and $29,000 for the years ended January 31, 2019 and 2018, respectively.
Income Taxes		Income Taxes The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when management estimates, based on available objective evidence, that it is more likely than not that the benefit will not be realized for the deferred tax assets. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. No interest expense was recognized during the periods presented.
Stock-Based Compensation		Stock-Based Compensation The Company recognizes stock-based compensation for equity awards on a straight-line basis over their vesting periods based on the grant date fair value. The Company estimates the fair value of stock options granted using the Black-Scholes pricing model. This model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
Comprehensive Loss		Comprehensive Loss Comprehensive loss is the change in equity of an enterprise, except those resulting from stockholder transactions. Accordingly, comprehensive loss includes certain changes in equity that are excluded from net loss. For the years ended January 31, 2019 and 2018, the Company’s comprehensive loss is equal to its net loss. There were no components of other comprehensive loss for any of the periods presented.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock outstanding during the period. The weighted-average shares outstanding for the three and nine months ended October 31, 2019 and 2018 excludes 7,733 shares of unvested restricted common stock. Diluted net loss per share attributable to common stockholders is calculated based on the weighted-average number of shares of the Company’s common stock outstanding and other dilutive securities outstanding during the period. As of October 31, 2019 and 2018, approximately 6,325,000 and 7,604,000 of potentially dilutive securities, respectively, were excluded from the computation of diluted net loss per share because their effect on net loss per share would be anti-dilutive.	Net Loss Per Share Basic net loss per share attributable to common stockholders is calculated based on the weighted average number of shares of the Company’s common stock outstanding during the period. The weighted average shares outstanding for the years ended January 31, 2019 and 2018 exclude 193,333 shares of unvested restricted common stock. Diluted net loss per share attributable to common stockholders is calculated based on the weighted average number of shares of the Company’s common stock outstanding and other dilutive securities outstanding during the period. As of January 31, 2019 and 2018, approximately 182,702,000 and 215,810,000, potentially dilutive securities, respectively, were excluded from the computation of diluted loss per share because their effect on net loss per share would be anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, Leases , and in July 2018, ASU No. 2018-11, Targeted Improvements , which requires entities to recognize assets and liabilities for leases with lease terms greater than twelve months. The Company adopted this standard as of February 1, 2019, and the Company’s leases are classified as operating leases and will continue to be classified as operating leases under the new accounting method. Adoption of the new standard resulted in the recording of an operating lease right-to-use asset of $1.2 million, which represents the present value of the remaining lease payments as of the date of adoption discounted using an incremental borrowing rate of 15%, and an operating lease liability of $1.3 million. The adoption did not have an impact on the Company’s condensed consolidated statement of operations and comprehensive loss or cash flows. See Note 9 for further information. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting , which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The amendment is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company adopted this update as of February 1, 2019 and the adoption did not have a material effect on its condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , which amended certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendment is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting this amendment, but does not anticipate it will have a material impact on its disclosures. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.	Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02, Leases , and in July 2018, ASU No. 2018-11, Targeted Improvements , which requires entities to recognize assets and liabilities for leases with lease terms greater than twelve months. The new guidance also requires quantitative and qualitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company does not expect a material impact on the statement of operations and comprehensive loss or cash flows from the adoption of this standard. In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting . This amendment impacts entities that change the terms or conditions of a share-based payment award. The Company adopted this guidance as of February 1, 2018 for awards that are modified after that date, and the adoption did not have a material effect on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting , which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The amendment is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated financial statements as a result of future adoption.

DESCRIPTION OF BUSINESS AND S_3

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Jan. 31, 2019
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of estimated useful lives of property and equipment	Estimated Description Useful Life Furniture 5 - 7 Laboratory equipment 3 - 5 Computer and equipment 3 - 5

BALANCE SHEET DETAILS (Tables)

BALANCE SHEET DETAILS (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
BALANCE SHEET DETAILS
Schedule of Inventories		January 31, 2019 2018 (in thousands) Inventories: Work in process $ — $ Finished goods — Channel inventory — $ — $ 10
Property and Equipment		January 31, 2019 2018 (in thousands) Property and equipment, net: Furniture $ — $ Laboratory equipment Computer and equipment Less: accumulated depreciation $ 148 $ 109
Schedule Accrued liabilities	October 31, January 31, 2019 2019 (in thousands) Accrued expenses and other current liabilities: Compensation $ 417 $ 371 Operating lease liability - current portion 260 — Research and development 119 399 Other 67 164 $ 863 $ 934	January 31, 2019 2018 (in thousands) Accrued liabilities: Research and development $ 399 $ 404 Payroll 371 368 Legal 45 438 Purchase commitment liability — 215 Deferred revenue — 8 Other 119 170 $ 934 $ 1,603

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
FAIR VALUE MEASUREMENTS
Schedule of Fair Value of Warrant Liability Classified as Level 3 Liabilities	The table below presents the activity within Level 3 of the fair value hierarchy (in thousands): Warrant Liability Balance as of February 1, 2019 $ 11 Change in fair value of warrants (9) Balance as of April 30, 2019 2 Change in fair value of warrants (2) Balance as of July 31, 2019 and October 31, 2019 $ —	The fair value of the warrant liability was classified as a Level 3 liability, as the Company uses unobservable inputs to value it. The table below presents the activity within Level 3 of the fair value hierarchy (in thousands): Warrant Liability Balance as of January 31, 2017 $ 403 Change in fair value of warrants (364) Balance as of January 31, 2018 39 Change in fair value of warrants (28) Balance as of January 31, 2019 $ 11

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Jan. 31, 2019
COMMITMENTS AND CONTINGENCIES
Future minimum commitments	The following table summarizes the Company’s commitments as of January 31, 2019 (in thousands): Fiscal years ending January 31, Total 2020 2021 2022 2023 2024 Operating lease $ 1,539 $ 280 $ 315 $ 324 $ 334 $ 286 Capital lease for laboratory equipment 47 22 22 3 — — Total $ 1,586 $ 302 $ 337 $ 327 $ 334 $ 286

CONVERTIBLE PREFERRED STOCK A_2

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Schedule of outstanding warrants	A summary of warrants outstanding as of October 31, 2019 is as follows: Total Price per Share Expiration Date Warrants related to November 2014 financing 19,762 $ 92.50 November 2019 Warrants related to June 2015 financing 4,363 $ 68.75 June 2020 Warrants related to April 2016 financing 70,581 $ 30.00 April 2021 Warrants related to September 2016 financing (1) 51,466 $ 18.75 September 2021 to March 2022 Warrants related to November 2016 financing 1,216,230 $ 8.75 November 2024 Warrants related to November 2016 financing 35,818 $10.938 November 2022 Warrants related to November 2016 financing 7,926 $ 8.25 November 2022 Warrants related to April 2017 financing 32,053 $ 22.50 October 2022 Warrants related to October 2017 financing 153,848 $ 7.50 October 2022 Warrants related to November 2017 financing 2,277,412 $ 5.00 November 2022 Warrants related to November 2018 financing (2) 1,066,670 $ 4.10 May/June 2021 4,936,129 (1) In connection with the sale of common stock in September 2016, warrants to purchase 51,466 shares of common stock were issued at an exercise price of $18.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of October 31, 2019, the fair value of the warrant liability was immaterial and was included in other long-term liabilities. (2) On November 20, 2018, the Company entered into agreements with holders of certain of its warrants to purchase common stock with an exercise price per share of $6.25 originally issued on November 24, 2017 (Existing Warrants), whereby the holders and the Company agreed that the holders would cash exercise up to 1,066,670 shares of common stock underlying such Existing Warrants at a reduced price of $3.50, and the Company would issue new warrants to such holders to purchase up to an aggregate of 1,066,670 shares of common stock (New Warrants). The New Warrants are exercisable after the six-month anniversary of their issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $4.10. The Company recorded a charge for the incremental fair value of approximately $874,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.51%, contractual term of 6 months, expected volatility of 78.4% and a dividend rate of 0%.	A summary of warrants outstanding as of January 31, 2019 is as follows: Total Price per Share Expiration Date Warrants related to January 2014 agreement 289,505 $ 1.85 May 2019 Warrants related to May 2014 agreement 316,395 $2.035 May 2019 Warrants related to April to November 2014 financing 1,661,055 $ 3.70 April 2019 - November 2019 Warrants related to June 2015 financing 109,091 $ 2.75 June 2020 Warrants related to April 2016 financing 1,952,000 $ 1.20 April 2021 Warrants related to September 2016 financing (1) 1,286,501 $ 0.75 September 2021 to March 2022 Warrants related to November 2016 financing 30,406,061 $ 0.35 November 2022 to November 2024 Warrants related to November 2016 financing 895,450 $ 0.44 November 2022 Warrants related to November 2016 financing 198,214 $ 0.33 November 2022 Warrants related to April 2017 financing 801,282 $ 0.90 October 2022 Warrants related to October 2017 financing (2) 3,846,152 $ 0.30 October 2022 Warrants related to November 2017 financing 56,935,191 $ 0.20 November 2022 Warrants related to November 2017 financing (3) 33,422,061 $ 0.25 May 2019 Warrants related to November 2018 financing (3) 26,666,666 $0.164 May/June 2021 (1) In connection with the sale of common stock in September 2016, warrants to purchase 1,286,501 shares of common stock were issued at an exercise price of $0.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of January 31, 2019, the fair value of the warrant liability was approximately $11,000 and was included as a long-term liability. (2) On October 23, 2017, the Company entered into agreements with certain of these warrant holders to permit their immediate exercise of 2,564,103 shares of common stock underlying the warrants at an exercise price per share of $0.24. The Company recorded a charge for the incremental fair value of approximately $151,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.03%, contractual term of 5 years, expected volatility of 83.9% and a dividend rate of 0%. In addition, these warrant holders were issued new warrants to purchase up to an aggregate of 3,846,152 shares of common stock at an exercise price per share of $0.30. (3) On November 20, 2018, the Company entered into agreements with holders of certain of its warrants to purchase common stock with an exercise price per share of $0.25 originally issued on November 24, 2017 (Existing Warrants), whereby the holders and the Company agreed that the holders would cash exercise 26,666,666 shares of common stock underlying such Existing Warrants at a reduced price of $0.14, and the Company would issue new warrants to such holders to purchase up to an aggregate of 26,666,666 shares of common stock (New Warrants). The New Warrants are exercisable after the six-month anniversary of their issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $0.164. The Company recorded a charge for the incremental fair value of approximately $874,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.51%, contractual term of 6 months, expected volatility of 78.4% and a dividend rate of 0%.
Schedule of significant ranges of outstanding and exercisable options	Options Outstanding Options Vested and Exercisable Weighted Average Weighted Weighted Remaining Average Number Average Number Contractual Exercise Vested and Exercise Range of Exercise Prices Outstanding Life (in Years) Prices Exercisable Prices $0.44 - $0.84 $ $ $0.85 - $4.00 $ $ $4.01 - $10.50 $ $ $10.51- $18.50 $ $ $18.51 - $28.50 $ $ $28.51 - $75.00 $ 14,354 $ 51.19 $ $	Options Outstanding Options Vested and Exercisable Weighted Average Weighted Weighted Remaining Average Number Average Number Contractual Exercise Vested and Exercise Range of Exercise Prices Outstanding Life (in Years) Prices Exercisable Prices $0.10 - $0.16 $ $ $0.17 - $0.35 $ $ $0.36 - $0.65 $ $ $0.66 - $1.14 $ $ $1.15 - $3.00 $ 1,003,748 $ 1.80 $ $
2014 Equity Incentive Plan
Stock option plan activity		Weighted Average Remaining Aggregate Available for Exercise Contractual Intrinsic Grant Shares Prices Life Value (in thousands) Balance as of February 1, 2017 252,379 6,465,829 $ $ 238 Shares authorized for issuance 20,000,000 — Granted (18,553,000) 18,553,000 $ Exercised — (40,000) $ Canceled and returned to the 2016 Plan 185,499 (185,499) $ Canceled subsequent to termination of the 2014 Plan — (68,667) $ Balance as of January 31, 2018 1,884,878 24,724,663 $ $ 304 Shares authorized for issuance 50,000,000 — Granted (10,444,000) 10,444,000 $ Exercised — (278,196) $ Canceled and returned to the 2016 Plan 11,262,538 (11,262,538) $ Canceled subsequent to termination of the 2014 Plan — (680,060) $ Balance as of January 31, 2019 52,703,416 22,947,869 $ $ 23 Vested and exercisable 9,257,545 $ $ 13 Vested and expected to vest 21,836,056 $ $ 22
Outside of the 2016 Equity Incentive Plan
Stock option plan activity	Weighted Average Remaining Exercise Contractual Aggregate Shares Prices Life Intrinsic Value (in thousands) Balance as of February 1, 2019 31,000 $ $ — Canceled (6,000) $ Balance as of April 30, 2019 25,000 $ $ — Canceled (750) $ Balance as of July 31, 2019 24,250 $ $ — Canceled (8,250) $ Balance as of October 31, 2019 16,000 $ $ — Vested and exercisable 6,667 $ $ — Vested and expected to vest 13,819 $ $ —	Weighted Average Remaining Exercise Contractual Aggregate Shares Prices Life Intrinsic Value (in thousands) Balance as of February 1, 2017 and 2018 660,000 $ $ — Granted 400,000 $ Canceled (285,000) $ Balance as of January 31, 2019 775,000 $ $ — Vested and exercisable 332,812 $ $ — Vested and expected to vest 747,437 $ $ —

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
STOCK-BASED COMPENSATION
Summary of stock based compensation expense	The following table summarizes the stock-based compensation expenses included in the condensed consolidated statement of operations and comprehensive loss (in thousands): For the three months ended For the nine months ended October 31, October 31, 2019 2018 2019 2018 Research and development $ 30 $ 166 $ 218 $ 525 Sales and marketing 12 114 45 355 General and administrative 187 438 334 877 Total $ 229 $ 718 $ 597 $ 1,757	The following table summarizes the stock-based compensation expenses included in the statements of operations and comprehensive loss (in thousands): Year ended January 31, 2019 2018 Research and development $ 654 $ 545 Sales and marketing 414 393 General and administrative 993 949 Total $ 2,061 $ 1,887
Black-Scholes option pricing model fair value assumptions	The following assumptions were used to calculate the estimated fair value of awards granted for the periods ended: For the three months ended For the nine months ended October 31, October 31, 2019 2018 2019 2018 Expected volatility — 78.8% - 91.0% 68.3% - 70.8% 78.8% - 91.0% Expected term in years — 4.0 - 8.6 4.0 - 8.6 Risk-free interest rate — 2.72% - 3.10% 1.88% - 2.51% 2.72% - 3.10% Expected dividend yield — — — —	Year ended January 31, 2019 2018 Expected volatility 78.8% - 91.0% 83.9% - 96.8% Expected term in years 4.0 6.0 - 9.39 Risk-free interest rate 2.43% - 2.98% 1.80% - 2.70% Expected dividend yield — —

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jan. 31, 2019
INCOME TAXES
Summary of components of deferred tax assets	Significant components of the Company’s deferred tax assets were as follows (in thousands): January 31, Deferred tax assets: 2019 2018 Net operating loss carryforwards $ 18,769 $ 14,314 Stock-based compensation expense 1,163 831 Tax credit carryforwards 1,022 735 Other 160 377 Total deferred tax assets 21,114 16,257 Less: valuation allowance (21,114) (16,257) Net deferred tax assets $ — $ —
Schedule of reconciliation of income taxes at the federal statutory rate to the actual income tax provision	A reconciliation of income taxes provided at the federal statutory rate (21% in 2019) to the actual income tax provision was as follows (in thousands): Year ended January 31, 2019 2018 Income tax benefit computed at U.S. statutory rate $ (3,624) $ (5,477) State income tax (net of federal benefit) (1,478) (1,150) Change in federal rate from 34% to 21% — 7,662 Change in valuation allowance 4,857 (1,039) Research and development credits (158) (129) Other 405 135 Provision for income taxes $ 2 $ 2

DESCRIPTION OF BUSINESS AND S_4

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - subsidiary	Oct. 31, 2019	Jan. 31, 2019
Other Disclosures
Number of wholly owned subsidiaries	1	1

DESCRIPTION OF BUSINESS AND S_5

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Assets and Expenses (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Advertising Expenses
Advertising expenses	$ 10,000	$ 29,000
Income taxes
Unrecognized tax benefits, interest on income tax expense	$ 0	$ 0
Furniture | Minimum
Property and Equipment
Estimated Useful Life	5 years
Furniture | Maximum
Property and Equipment
Estimated Useful Life	7 years
Laboratory Equipment | Minimum
Property and Equipment
Estimated Useful Life	3 years
Laboratory Equipment | Maximum
Property and Equipment
Estimated Useful Life	5 years
Computer and equipment | Minimum
Property and Equipment
Estimated Useful Life	3 years
Computer and equipment | Maximum
Property and Equipment
Estimated Useful Life	5 years

DESCRIPTION OF BUSINESS AND S_6

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details) - ASU 2014-09 - ASC 606 Adjustment	Feb. 01, 2018USD ($)
Revenue Recognition
Accumulated deficit adjustment	$ 2,000
Deferred revenue decrease	$ 2,000

DESCRIPTION OF BUSINESS AND S_7

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Net Loss Per Share
Unvested restricted common shares	7,733	7,733	7,733	7,733	193,333	193,333
Potentially dilutive securities excluded from computation of diluted loss per share			6,325,000	7,604,000	182,702,000	215,810,000

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2017
GOING CONCERN
Cash and cash equivalents	$ 1,427		$ 1,427		$ 3,069	$ 7,576	$ 6,501
Working capital	300		300		1,100
Net loss	2,113	$ 4,390	8,380	$ 13,200	17,256	16,638
Accumulated deficit	$ 86,916		$ 86,916		$ 78,534	$ 61,278

BALANCE SHEET DETAILS (Details)

BALANCE SHEET DETAILS (Details) - USD ($)	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018	May 31, 2019	Mar. 31, 2018
Inventories:
Work in process				$ 5,000
Finished goods				1,000
Channel inventory				4,000
Total				10,000
Property and equipment, net:
Property and equipment, gross			$ 325,000	243,000
Less: accumulated depreciation			(177,000)	(134,000)
Property and equipment, net	$ 186,000		148,000	109,000
Depreciation	$ 46,000	$ 48,000	62,000	52,000
Furniture
Property and equipment, net:
Property and equipment, gross				21,000
Laboratory Equipment
Property and equipment, net:
Property and equipment, gross			196,000	106,000
Property and equipment, net					$ 54,000	$ 61,000
Computer and equipment
Property and equipment, net:
Property and equipment, gross			$ 129,000	$ 116,000

BALANCE SHEET DETAILS - Accrued

BALANCE SHEET DETAILS - Accrued Liabilities (Details) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Accrued liabilities:
Research and development	$ 119	$ 399	$ 404
Payroll	417	371	368
Legal		45	438
Purchase commitment liability			215
Deferred Revenue			8
Other	67	164	170
Total	$ 863	$ 934	$ 1,603

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Level 1 - Money Market Funds - USD ($) $ in Millions	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Fair Value Measurements
Available-for-sale securities	$ 2.5	$ 7.1
Unrealized gains (losses)	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Fair

FAIR VALUE MEASUREMENTS - Fair Value of Warrant Liability Classified as Level 3 Liabilities (Details) - Level 3 - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Jan. 31, 2018
Fair Value of Warrant Liability Classified as Level 3 Liabilities
Beginning balance		$ 11	$ 39	$ 403
Change in fair value of warrants	$ (2)	(9)	(28)	(364)
Ending balance		$ 2	$ 11	$ 39

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Commitments (Details)	1 Months Ended	12 Months Ended
	Mar. 31, 2018USD ($)	Jan. 31, 2019USD ($)ft²	Jan. 31, 2018USD ($)
Operating lease
2020		$ 280,000
2021		315,000
2022		324,000
2023		334,000
2024		286,000
Total		1,539,000
Capital lease for laboratory equipment
2020		22,000
2021		22,000
2022		3,000
Total		47,000
Total
2020		302,000
2021		337,000
2022		327,000
2023		334,000
2024		286,000
Total		1,586,000
Rent expense
Rent expense		586,000	$ 612,000
Capital lease obligation	$ 61,000
Future payments representing interest	$ 5,000
CRO agreements, remaining cost		$ 800,000
San Jose, California
Rent expense
Leased office and laboratory area | ft²		11,793

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - Legal Proceedings and License Agreement (Details)	Jan. 31, 2019USD ($)
COMMITMENTS AND CONTINGENCIES
Estimated claim liability	$ 0

CONVERTIBLE PREFERRED STOCK A_3

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended			9 Months Ended	12 Months Ended
	Mar. 31, 2019	Nov. 30, 2017	Jul. 31, 2017	Apr. 30, 2017	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Oct. 31, 2019	Jan. 31, 2018
Net proceeds from the sale of common stock								$ 7,200
Beneficial ownership interest if common stock issued (as a percentage)		9.99%
Minimum
Beneficial ownership interest if common stock issued (as a percentage)		4.99%
Common Stock
Issuance of stock (in shares)		45,275,000			1,040,308	3,707,504	1,745,800		57,185,258
Warrant
Net proceeds from issuance of common stock and warrants		$ 9,700
Prefunded warrants
Warrants exercise price (in dollars per share)		$ 0.001
Prefunded warrants | Warrant
Number of shares of common stock subject to warrant (in shares)		28,225,000
Series A Warrants | Warrant
Number of shares of common stock subject to warrant (in shares)		73,500,000
Warrants exercise price (in dollars per share)		$ 0.20
Warrants, expiration term		5 years
Series B Warrants | Warrant
Number of shares of common stock subject to warrant (in shares)		73,500,000
Warrants exercise price (in dollars per share)		$ 0.25
Warrants exercisable after number of trading days from a press release		20 days
Warrants exercisable after number of months from issuance		18 months
Prefunded warrants and series A | Common Stock
Number of common shares called by each warrant (in shares)		1
Prefunded warrants and series B | Common Stock
Number of common shares called by each warrant (in shares)		1
Prefunded warrants, series A and series B | Warrant
Warrants exercise price (in dollars per share)		$ 0.1490
Series A and series B | Common Stock
Warrants exercise price (in dollars per share)		$ 0.15
Private placement
Issuance of stock (in shares)	1,745,800		5,500,000	6,410,258
Net proceeds from the sale of common stock	$ 3,600		$ 1,900	$ 4,400
Share price (in dollars per share)	$ 0.09		$ 0.36	$ 0.78
Number of shares of common stock subject to warrant (in shares)				3,365,385
Warrants exercise price (in dollars per share)				$ 0.90

CONVERTIBLE PREFERRED STOCK A_4

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - Preferred Stock & Warrants (Details)

Nov. 20, 2018USD ($)shares

Oct. 23, 2017USD ($)$ / sharesshares

Nov. 30, 2016USD ($)$ / sharesshares

Oct. 31, 2018USD ($)

Jan. 31, 2019USD ($)$ / sharesshares

Jan. 31, 2018USD ($)shares

Oct. 31, 2019$ / sharesshares

Mar. 31, 2019$ / shares

Nov. 20, 2018$ / shares

Nov. 20, 2018shares

Nov. 20, 2018

Nov. 20, 2018item

Nov. 24, 2017$ / shares

Jul. 31, 2017$ / shares

Apr. 30, 2017$ / sharesshares

Sep. 30, 2016

Sep. 30, 2016$ / shares

Sep. 30, 2016shares

Sep. 30, 2016

Sep. 30, 2016USD ($)

Sep. 30, 2016item

Equity

Proceeds from warrant exercises to purchase common stock | $

$ 6,961,000

$ 10,546,000

$ 644,000

Series A convertible preferred stock, shares authorized

10,000,000

10,000,000

10,000,000

Series A convertible preferred stock, shares issued

0

0

0

Incremental fair value of warrants | $

$ 874,000

$ 151,000

Private placement

Equity

Share price (in dollars per share) | $ / shares

$ 0.09

$ 0.36

$ 0.78

Warrants exercise price (in dollars per share) | $ / shares

$ 0.90

Number of shares of common stock subject to warrant (in shares)

3,365,385

Warrant

Equity

Warrants outstanding

4,936,129

Warrant | Public Offering

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.35

Number of shares of common stock subject to warrant (in shares)

3,246,429

Warrant | Series B Warrants

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 6.25

$ 3.50

Issuance of common stock due to exercise of warrants (in shares)

1,066,670

Warrant | New Warrants

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 4.10

Warrants expiry after number of months from issuance

30 months

Warrants exercisable period after anniversary of issuance (in months)

6 months

Warrant | New Warrants | Maximum

Equity

Number of shares of common stock subject to warrant (in shares)

1,066,670

Warrants related to January 2014 agreement | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 1.85

Warrants outstanding

289,505

Warrants related to May 2014 agreement | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 2.035

Warrants outstanding

316,395

Warrants related to April to November 2014 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 3.70

Warrants outstanding

1,661,055

Warrants related to June 2015 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 2.75

$ 68.75

Warrants outstanding

109,091

4,363

Warrants related to April 2016 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 1.20

$ 30

Warrants outstanding

1,952,000

70,581

Warrants related to September 2016 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.75

$ 18.75

$ 18.75

Warrant liability | $

$ 11,000

$ 566,000

Number of shares of common stock subject to warrant (in shares)

51,466

Warrants outstanding

1,286,501

51,466

Warrants related to September 2016 financing | Warrant | Risk-free interest rate

Equity

Warrants, measurement input

1.1

1.1

Warrants related to September 2016 financing | Warrant | Contractual term

Equity

Warrants, contractual term

5 years

Warrants related to September 2016 financing | Warrant | Expected volatility

Equity

Warrants, measurement input

95.8

95.8

Warrants related to September 2016 financing | Warrant | Dividend rate

Equity

Warrants, measurement input

0

0

Warrants related to November 2016 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.35

$ 8.75

Warrants outstanding

30,406,061

1,216,230

Warrants related to November 2016 financing, tranche two | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.44

$ 10.938

Warrants outstanding

895,450

35,818

Warrants related to November 2016 financing, tranche three | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.33

$ 8.25

Warrants outstanding

198,214

7,926

Warrants related to April 2017 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.90

$ 22.50

Warrants outstanding

801,282

32,053

Warrants related to October 2017 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.24

$ 0.30

$ 7.50

Number of shares of common stock subject to warrant (in shares)

2,564,103

Warrants outstanding

3,846,152

153,848

Incremental fair value of warrants | $

$ 151,000

Warrants related to October 2017 financing | Warrant | Risk-free interest rate

Equity

Warrants, measurement input

2.03

Warrants related to October 2017 financing | Warrant | Contractual term

Equity

Warrants, contractual term

5 years

Warrants related to October 2017 financing | Warrant | Expected volatility

Equity

Warrants, measurement input

83.9

Warrants related to October 2017 financing | Warrant | Dividend rate

Equity

Warrants, measurement input

0

Warrants related to November 2017 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.20

$ 5

Warrants outstanding

56,935,191

2,277,412

Warrants related to November 2017 financing, tranche two | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.25

Warrants outstanding

33,422,061

Incremental fair value of warrants | $

$ 874,000

Warrants related to November 2017 financing, tranche two | Warrant | Risk-free interest rate

Equity

Warrants, measurement input

2.51

Warrants related to November 2017 financing, tranche two | Warrant | Contractual term

Equity

Warrants, contractual term

6 months

Warrants related to November 2017 financing, tranche two | Warrant | Expected volatility

Equity

Warrants, measurement input

78.4

78.4

Warrants related to November 2017 financing, tranche two | Warrant | Dividend rate

Equity

Warrants, measurement input

0

0

Warrants related To November 2018 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.164

$ 4.10

Warrants outstanding

26,666,666

1,066,670

Common Stock | Warrants related to October 2017 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.30

Warrants outstanding

3,846,152

Series A convertible redeemable preferred stock | Public Offering

Equity

Share price (in dollars per share) | $ / shares

$ 1,000

Series A Convertible Preferred Stock

Equity

Series A convertible preferred stock, shares authorized

10,000

Series A convertible preferred stock, shares issued

1,515

Deemed dividend related to the beneficial conversion feature | $

$ 100,000

Number of common shares into which a share is convertible

4,328,571

CONVERTIBLE PREFERRED STOCK A_5

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - Equity Incentive Plan (Details) - 2016 Equity Incentive Plan - shares	1 Months Ended		9 Months Ended	12 Months Ended
	Aug. 31, 2018	Mar. 31, 2017	Oct. 31, 2019	Jan. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award
Additional shares authorized	2,000,000	800,000
Number of shares reserved for issuance	2,960,000	960,000
Options
Share-based Compensation Arrangement by Share-based Payment Award
Expiration period			10 years	10 years
Minimum | Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period			1 year	1 year
Maximum | Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period			4 years	4 years

CONVERTIBLE PREFERRED STOCK A_6

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - Stock Option Activities (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended			9 Months Ended	12 Months Ended
	Aug. 31, 2018	Mar. 31, 2017	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2017
Weighted Average Exercise Prices
Granted							$ 0.12	$ 0.21
Plans
Available for Grant
Available for grant, beginning			1,507,589	2,160,035	2,107,575	2,107,575	1,884,878	252,379
Shares authorized for issuance							50,000,000	20,000,000
Granted				(877,100)	(16,720)		(10,444,000)	(18,553,000)
Available for grant, ending			1,612,728	1,507,589	2,160,035	1,612,728	2,107,575	1,884,878	252,379
Shares
Outstanding, Beginning			1,481,444	835,338	917,945	917,945	24,724,663	6,465,829
Granted				877,100	16,720		10,444,000	18,553,000
Exercised				0	(1,667)		(278,196)	(40,000)
Outstanding, Ending			1,364,827	1,481,444	835,338	1,364,827	917,945	24,724,663	6,465,829
Vested and exercisable			421,764			421,764	9,257,545
Vested and expected to vest			1,137,123			1,137,123	21,836,056
Weighted Average Exercise Prices
Outstanding, Beginning			$ 4.44	$ 8.27	$ 9.02	$ 9.02	$ 0.41	$ 0.77
Granted				0.80	3.21		0.21	0.29
Exercised					2.50		0.10	0.25
Outstanding, Ending			3.93	$ 4.44	$ 8.27	3.93	9.02	$ 0.41	$ 0.77
Vested and exercisable			7.56			7.56	0.53
Vested and expected to vest			$ 4.26			$ 4.26	$ 0.37
Remaining Contractual Life
Outstanding			8 years 11 months 12 days	8 years 7 months 13 days	8 years 4 months 6 days		7 years 11 months 1 day	9 years 2 months 1 day	8 years 9 months 7 days
Vested and exercisable			8 years 18 days				5 years 11 months 5 days
Vested and expected to vest			8 years 10 months 13 days				7 years 10 months 6 days
Aggregate Intrinsic Value
Outstanding							$ 23	$ 304	$ 238
Vested and exercisable							13
Vested and expected to vest							$ 22
Subsequent to termination of the 2014 plan
Available for Grant
Cancelled							680,060	68,667
Shares
Cancelled							(680,060)	(68,667)
Weighted Average Exercise Prices
Cancelled							$ 1.01	$ 1.48
2016 Equity Incentive Plan
Available for Grant
Shares authorized for issuance	2,000,000	800,000
Cancelled			105,139	224,654	69,180		11,262,538	185,499
Shares
Cancelled			(105,139)	(224,654)	(69,180)		(11,262,538)	(185,499)
Weighted Average Exercise Prices
Cancelled			$ 8.54	$ 4.18	$ 8.84		$ 0.30	$ 0.65
Outside the 2014 Equity Incentive Plan
Available for Grant
Granted							(400,000)
Cancelled							285,000
Shares
Outstanding, Beginning					775,000	775,000	660,000	660,000
Granted							400,000
Cancelled							(285,000)
Outstanding, Ending							775,000	660,000	660,000
Vested and exercisable							332,812
Vested and expected to vest							747,437
Weighted Average Exercise Prices
Outstanding, Beginning					$ 0.71	$ 0.71	$ 1.44	$ 1.44
Granted							0.19
Cancelled							1.65
Outstanding, Ending							0.71	$ 1.44	$ 1.44
Vested and exercisable							1.30
Vested and expected to vest							$ 0.73
Remaining Contractual Life
Outstanding							6 years 7 months 6 days	7 years 8 months 19 days	7 years 8 months 19 days
Vested and exercisable							3 years 8 months 12 days
Vested and expected to vest							6 years 6 months 7 days
Outside the 2014 Equity Incentive Plan | First anniversary
Available for Grant
Vesting percentage							25.00%
Outside the 2014 Equity Incentive Plan | Subsequent to first anniversary
Available for Grant
Vesting percentage							2.083%

CONVERTIBLE PREFERRED STOCK A_7

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - Range of Exercise Price (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Options Outstanding
Number Outstanding (in shares)		1,380,827		23,722,869
Weighted Average Remaining Contractual Life		8 years 11 months 9 days		7 years 10 months 17 days
Weighted Average Exercise Prices (in dollars per share)		$ 3.94		$ 0.37
Options Exercisable
Number Vested and Exercisable (in shares)		428,431		9,590,357
Weighted Average Exercise Prices (in dollars per share)		$ 7.52		$ 0.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Total intrinsic value of options exercised	$ 24,000		$ 26,000	$ 26,000	$ 4,000
$0.10 - $0.16
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)		0.44		$ 0.10
Exercise prices, high end of range (in dollars per share)		$ 0.84		$ 0.16
Options Outstanding
Number Outstanding (in shares)		758,134		5,503,893
Weighted Average Remaining Contractual Life		9 years 7 months 13 days		8 years 1 month 2 days
Weighted Average Exercise Prices (in dollars per share)		$ 0.79		$ 0.11
Options Exercisable
Number Vested and Exercisable (in shares)		104,257		2,619,037
Weighted Average Exercise Prices (in dollars per share)		$ 0.81		$ 0.10
$0.17 - $0.35
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)		0.85		0.17
Exercise prices, high end of range (in dollars per share)		$ 4		$ 0.35
Options Outstanding
Number Outstanding (in shares)		109,639		11,347,484
Weighted Average Remaining Contractual Life		8 years 29 days		9 years 7 days
Weighted Average Exercise Prices (in dollars per share)		$ 2.56		$ 0.22
Options Exercisable
Number Vested and Exercisable (in shares)		81,389		1,728,162
Weighted Average Exercise Prices (in dollars per share)		$ 2.54		$ 0.23
$0.36 - $0.65
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)		4.01		0.36
Exercise prices, high end of range (in dollars per share)		$ 10.50		$ 0.65
Options Outstanding
Number Outstanding (in shares)		410,769		2,567,126
Weighted Average Remaining Contractual Life		8 years 7 months 2 days		6 years 1 month 13 days
Weighted Average Exercise Prices (in dollars per share)		$ 5.60		$ 0.53
Options Exercisable
Number Vested and Exercisable (in shares)		154,321		1,974,108
Weighted Average Exercise Prices (in dollars per share)		$ 5.88		$ 0.53
$0.66 to $1.14
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)		10.51		0.66
Exercise prices, high end of range (in dollars per share)		$ 18.50		$ 1.14
Options Outstanding
Number Outstanding (in shares)		78,244		3,266,554
Weighted Average Remaining Contractual Life		6 years 5 months 9 days		6 years 5 months 5 days
Weighted Average Exercise Prices (in dollars per share)		$ 16.79		$ 0.78
Options Exercisable
Number Vested and Exercisable (in shares)		64,510		2,265,302
Weighted Average Exercise Prices (in dollars per share)		$ 16.72		$ 0.79
$1.15 to $3.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)		18.51		1.15
Exercise prices, high end of range (in dollars per share)		$ 28.50		$ 3
Options Outstanding
Number Outstanding (in shares)		9,600		1,037,812
Weighted Average Remaining Contractual Life		5 years 8 months 27 days		3 years 3 months
Weighted Average Exercise Prices (in dollars per share)		$ 21.79		$ 1.79
Options Exercisable
Number Vested and Exercisable (in shares)		9,600		1,003,748
Weighted Average Exercise Prices (in dollars per share)		$ 21.79		$ 1.80
Options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Exercised				138,157

STOCK-BASED COMPENSATION - Expe

STOCK-BASED COMPENSATION - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Share-based Compensation
Stock-based compensation expense	$ 229	$ 718	$ 597	$ 1,757	$ 2,061	$ 1,887
Total compensation costs not yet recognized	1,000		$ 1,000		$ 2,000
Average remaining amortization period for recognition of expense			2 years 3 months 18 days		2 years 8 months 19 days
Research and development
Share-based Compensation
Stock-based compensation expense	30	166	$ 218	525	$ 654	545
Sales and marketing
Share-based Compensation
Stock-based compensation expense	12	114	45	355	414	393
General and administrative
Share-based Compensation
Stock-based compensation expense	$ 187	$ 438	$ 334	$ 877	$ 993	$ 949

STOCK-BASED COMPENSATION - Assu

STOCK-BASED COMPENSATION - Assumptions (Details)	3 Months Ended	9 Months Ended		12 Months Ended
	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award
Expected term in years		4 years		4 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award
Expected volatility	78.80%	68.30%	78.80%	78.80%	83.90%
Expected term in years	4 years		4 years		6 years
Risk-free interest rate	2.72%	1.88%	2.72%	2.43%	1.80%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award
Expected volatility	91.00%	70.80%	91.00%	91.00%	96.80%
Expected term in years	8 years 7 months 6 days		8 years 7 months 6 days		9 years 4 months 21 days
Risk-free interest rate	3.10%	2.51%	3.10%	2.98%	2.70%

EMPLOYEE BENEFIT PLAN (Details)

EMPLOYEE BENEFIT PLAN (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
EMPLOYEE BENEFIT PLAN
Employee maximum contribution percentage	100.00%
Employer discretionary contribution amount	$ 0	$ 0

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Federal income taxes	$ 0	$ 0
Increase in valuation allowance	4,900	1,000
Deferred tax Assets	21,114	$ 16,257
Federal
Operating loss carryforwards	68,600
State | California
Operating loss carryforwards	$ 62,400

INCOME TAXES - Components of De

INCOME TAXES - Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Jan. 31, 2019	Jan. 31, 2018
Deferred tax assets:
Net operating loss carryforwards	$ 18,769	$ 14,314
Stock-based compensation expense	1,163	831
Tax credit carryforwards	1,022	735
Other	160	377
Total deferred tax assets	21,114	16,257
Less: Valuation allowance	(21,114)	(16,257)
Net deferred tax assets

INCOME TAXES - Reconciliation o

INCOME TAXES - Reconciliation of Income Tax Provision (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Reconciliation of income taxes:
Income tax benefit computed at U.S. statutory rate			$ (3,624)	$ (5,477)
State income tax (net of federal benefit)			(1,478)	(1,150)
Change in federal rate from 34% to 21%				7,662
Change in valuation allowance			4,857	(1,039)
Research and development credits			(158)	(129)
Other			405	135
Income tax provision	$ 2	$ 2	$ 2	$ 2
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%	34.00%

CONDENSED CONSOLIDATED BALANC_3

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019
Current assets:
Cash and cash equivalents	$ 1,427	$ 3,069
Prepaid expenses and other	391	316
Total current assets	1,818	3,385
Property and equipment, net	186	148
Operating lease right-of-use asset, net	1,002
Other	121	121
Total assets	3,127	3,654
Current liabilities:
Accounts payable	687	1,363
Accrued expenses and other	863	934
Total current liabilities	1,550	2,297
Long-term liabilities:
Non-current operating lease liability	826
Other	34	59
Total liabilities	2,410	2,356
Commitments and contingencies (Note 5)
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of October 31, 2019 and January 31, 2019
Common stock, $0.001 par value; 450,000,000 shares authorized; 15,227,891 and 8,732,612 shares issued and outstanding as of October 31, 2019 and January 31, 2019, respectively	15	9
Additional paid-in capital	87,618	79,823
Accumulated deficit	(86,916)	(78,534)
Total stockholders' equity	717	1,298
Total liabilities and stockholders' equity	$ 3,127	$ 3,654

CONDENSED CONSOLIDATED BALANC_4

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 31, 2019	Apr. 25, 2019	Jan. 31, 2019	Jan. 31, 2018
CONDENSED CONSOLIDATED BALANCE SHEETS
Series A convertible preferred stock, par value	$ 0.001		$ 0.001	$ 0.001
Series A convertible preferred stock, shares authorized	10,000,000		10,000,000	10,000,000
Series A convertible preferred stock, shares issued	0		0	0
Series A convertible preferred stock, shares outstanding	0		0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000		450,000,000	450,000,000
Common stock, shares issued	15,227,891		8,732,612	160,062,509
Common stock, shares outstanding	15,227,891		8,732,612	160,062,509

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended						9 Months Ended		12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenues, net				$ 10				$ 52	$ 57	$ 73
Cost of goods sold				60				80	83	250
Gross margin				(50)				(28)	(26)	(177)
Operating expenses:
Research and development	$ 740			2,228			$ 4,314	7,285	9,079	9,140
Sales and marketing	139			550			572	1,717	2,157	2,415
General and administrative	1,241			1,624			3,534	4,252	5,244	5,144
Total operating expenses	2,120			4,402			8,420	13,254	16,480	16,699
Loss from operations	(2,120)			(4,452)			(8,420)	(13,282)	(16,506)	(16,876)
Change in fair value of warrant liability				42			11	(1)	28	364
Other income, net	7			20			29	83	(778)	(126)
Loss before provision for income taxes	(2,113)			(4,390)			(8,380)	(13,200)	(17,256)	(16,638)
Provision for income taxes							2	2	2	2
Net loss and comprehensive loss	$ (2,113)	$ (2,646)	$ (3,623)	$ (4,390)	$ (4,410)	$ (4,402)	$ (8,382)	$ (13,202)	$ (17,258)	$ (16,640)
Basic and diluted net loss per share	$ (0.14)			$ (0.57)			$ (0.69)	$ (1.76)	$ (0.09)	$ (0.19)
Shares used in computing basic and diluted net loss per share	14,672,000			7,654,000			12,146,000	7,502,000	193,178,000	85,900,000

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance Beginning, Amount at Jan. 31, 2017	$ 68	$ 46,026	$ (44,638)	$ 2,971
Balance Beginning, Shares at Jan. 31, 2017	67,719,577
Increase (decrease) in stockholders' deficit
Issuance of common stock, net of issuance costs	$ 57	15,992		16,049
Issuance of common stock, net of issuance costs (in shares)	57,185,258
Issuance of common stock due to exercise of options		10		10
Issuance of common stock due to exercise of options (in shares)	40,000
Issuance of common stock due to exercise of warrants	$ 31	613		644
Issuance of common stock due to exercise of warrants (in shares)	30,789,103
Stock-based compensation expense		1,887		1,887
Net and comprehensive loss			(16,640)	(16,640)
Balance Ending, Amount at Jan. 31, 2018	$ 6	66,344	(61,278)	5,072
Balance Ending, Shares at Jan. 31, 2018	6,402,500
Increase (decrease) in stockholders' deficit
Cumulative-effect adjustment from adoption of new accounting pronouncement			2	2
Issuance of common stock due to exercise of options	$ 1			1
Issuance of common stock due to exercise of options (in shares)	406
Issuance of common stock due to exercise of warrants	$ 1	6,960		6,961
Issuance of common stock due to exercise of warrants (in shares)	1,257,843
Stock-based compensation expense		593		593
Net and comprehensive loss			(4,402)	(4,402)
Balance Ending, Amount at Apr. 30, 2018	$ 8	73,897	(65,678)	8,227
Balance Ending, Shares at Apr. 30, 2018	7,660,749
Balance Beginning, Amount at Jan. 31, 2018	$ 6	66,344	(61,278)	5,072
Balance Beginning, Shares at Jan. 31, 2018	6,402,500
Increase (decrease) in stockholders' deficit
Net and comprehensive loss				(13,202)
Balance Ending, Amount at Oct. 31, 2018	$ 8	75,061	(74,478)	591
Balance Ending, Shares at Oct. 31, 2018	7,665,945
Balance Beginning, Amount at Jan. 31, 2018	$ 6	66,344	(61,278)	5,072
Balance Beginning, Shares at Jan. 31, 2018	6,402,500
Increase (decrease) in stockholders' deficit
Cumulative-effect adjustment from adoption of new accounting pronouncement			2	2
Issuance of common stock due to exercise of options		1		1
Issuance of common stock due to exercise of options (in shares)	140,039
Issuance of common stock due to exercise of warrants	$ 58	10,488		10,546
Issuance of common stock due to exercise of warrants (in shares)	58,112,748
Stock-based compensation expense		2,061		2,061
Net and comprehensive loss			(17,258)	(17,258)
Balance Ending, Amount at Jan. 31, 2019	$ 9	79,823	(78,534)	1,298
Balance Ending, Shares at Jan. 31, 2019	8,732,612
Balance Beginning, Amount at Apr. 30, 2018	$ 8	73,897	(65,678)	8,227
Balance Beginning, Shares at Apr. 30, 2018	7,660,749
Increase (decrease) in stockholders' deficit
Issuance of common stock due to exercise of options (in shares)	222
Stock-based compensation expense		446		446
Net and comprehensive loss			(4,410)	(4,410)
Balance Ending, Amount at Jul. 31, 2018	$ 8	74,343	(70,088)	4,263
Balance Ending, Shares at Jul. 31, 2018	7,660,971
Increase (decrease) in stockholders' deficit
Issuance of common stock due to exercise of options (in shares)	4,974
Stock-based compensation expense		718		718
Net and comprehensive loss			(4,390)	(4,390)
Balance Ending, Amount at Oct. 31, 2018	$ 8	75,061	(74,478)	591
Balance Ending, Shares at Oct. 31, 2018	7,665,945
Balance Beginning, Amount at Jan. 31, 2019	$ 9	79,823	(78,534)	1,298
Balance Beginning, Shares at Jan. 31, 2019	8,732,612
Increase (decrease) in stockholders' deficit
Issuance of common stock, net of issuance costs	$ 1	3,553		3,554
Issuance of common stock, net of issuance costs (in shares)	1,745,800
Issuance of common stock due to exercise of options		4		4
Issuance of common stock due to exercise of options (in shares)	1,667
Stock-based compensation expense		191		191
Net and comprehensive loss			(3,623)	(3,623)
Balance Ending, Amount at Apr. 30, 2019	$ 10	83,571	(82,157)	1,424
Balance Ending, Shares at Apr. 30, 2019	10,480,079
Balance Beginning, Amount at Jan. 31, 2019	$ 9	79,823	(78,534)	1,298
Balance Beginning, Shares at Jan. 31, 2019	8,732,612
Increase (decrease) in stockholders' deficit
Net and comprehensive loss				(8,382)
Balance Ending, Amount at Oct. 31, 2019	$ 15	87,618	(86,916)	717
Balance Ending, Shares at Oct. 31, 2019	15,227,891
Balance Beginning, Amount at Apr. 30, 2019	$ 10	83,571	(82,157)	1,424
Balance Beginning, Shares at Apr. 30, 2019	10,480,079
Increase (decrease) in stockholders' deficit
Issuance of common stock, net of issuance costs	$ 4	3,253		3,257
Issuance of common stock, net of issuance costs (in shares)	3,707,504
Stock-based compensation expense		177		177
Net and comprehensive loss			(2,646)	(2,646)
Balance Ending, Amount at Jul. 31, 2019	$ 14	87,001	(84,803)	2,212
Balance Ending, Shares at Jul. 31, 2019	14,187,583
Increase (decrease) in stockholders' deficit
Issuance of common stock, net of issuance costs	$ 1	388		389
Issuance of common stock, net of issuance costs (in shares)	1,040,308
Stock-based compensation expense		229		229
Net and comprehensive loss			(2,113)	(2,113)
Balance Ending, Amount at Oct. 31, 2019	$ 15	$ 87,618	$ (86,916)	$ 717
Balance Ending, Shares at Oct. 31, 2019	15,227,891

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jul. 31, 2019	Apr. 30, 2019	Jan. 31, 2018
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Issuance costs	$ 200	$ 400	$ 1,907

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Cash flows from operating activities:
Net loss	$ (8,382)	$ (13,202)	$ (17,258)	$ (16,640)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	597	1,757	2,061	1,887
Fair value modification of warrants			874	151
Depreciation expense	46	48	62	52
Change in fair value of warrant liability	(11)	1	(28)	(364)
Changes in assets and liabilities:
Prepaid expenses and other assets	(75)	(157)	(32)	75
Accounts payable	(676)	11	(13)	(1,175)
Accrued expenses and other liabilities	(290)	49	(661)	427
Net cash used in operating activities	(8,791)	(11,493)	(14,992)	(15,587)
Cash flows from investing activities:
Purchases of property and equipment	(30)	(13)	(43)	(41)
Net cash used in investing activities	(30)	(13)	(43)	(41)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs	7,200
Proceeds from exercises of common stock warrants		6,961	10,546	644
Proceeds from exercises of stock options	4	1	1	10
Payments on financing lease obligation	(25)	(14)	(19)
Net cash provided by financing activities	7,179	6,948	10,528	16,703
Net decrease in cash and cash equivalents	(1,642)	(4,558)
Cash and cash equivalents as of beginning of period	3,069	7,576	7,576
Cash and cash equivalents as of end of period	1,427	3,018	$ 3,069	$ 7,576
Non-cash investing activities:
Property and equipment acquired through finance lease	$ 54	$ 61

DESCRIPTION OF BUSINESS AND S_8

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business BioPharmX Corporation (the Company) is incorporated under the laws of the state of Delaware and originally incorporated on August 30, 2010 in Nevada under the name Thompson Designs, Inc. The Company has one wholly-owned subsidiary, BioPharmX, Inc., a Nevada corporation. The Company is a specialty pharmaceutical company focused on the dermatology market. Its focus is to develop products that treat dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal. Its strategy is to bring new products to market by identifying optimal delivery mechanisms and/or alternative applications for United States Food and Drug Administration (FDA) approved or well characterized active pharmaceutical ingredients (APIs). The Company aims to reduce the time, cost and risks typically associated with new product development by utilizing APIs with demonstrated safety profiles and, when applicable, taking advantage of the regulatory approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Section 505(b)(2) permits an applicant for a new product, such as a new or improved formulation or a new use of an approved product, to rely in part on literature and/or the FDA’s findings of safety and/or effectiveness for a similar previously-approved product. The Company’s approach is to identify the limitations of current treatment options and work to develop novel products using its proprietary HyantX™ topical drug delivery system. Since the Company’s inception, substantially all of the Company’s efforts have been devoted to developing its product candidates, including conducting preclinical and clinical trials, and providing general and administrative support for its operations. The Company has financed its operations primarily through the sale of equity and convertible notes. Basis of Presentation and Principles of Consolidation These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended January 31, 2019, filed on March 14, 2019. The condensed consolidated balance sheet as of January 31, 2019, included herein, was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared on the same basis as the audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s statement of financial position as of October 31, 2019 and January 31, 2019, and the Company’s results of operations for the three and nine months ended October 31, 2019 and 2018 and cash flows for the nine months ended October 31, 2019 and 2018. The results for the three and nine months ended October 31, 2019 are not necessarily indicative of the results to be expected for the year ending January 31, 2020 or any future period. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates. Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation. Accounts receivable have been included in prepaid expenses and other current assets in the condensed consolidated balance sheets. The amount for the prior period has been reclassified to be consistent with the current year presentation and has no impact on previously reported total assets, total stockholders’ equity or net loss. Reverse Stock Split On April 25, 2019, the Company effected a 1-for-25 reverse stock split of its common stock. As a result of the reverse stock split, every twenty-five shares of the Company’s pre-reverse split outstanding common stock was combined and reclassified into one share of common stock. Par value per share remained unchanged at $0.001 per share. Proportionate voting rights and other rights of common stockholders were not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split; stockholders who would otherwise hold a fractional share of common stock received cash in an amount equal to the product obtained by multiplying (i) the closing price of the Company’s common stock on the last trading day prior to the effective date of the reverse stock split, by (ii) the number of shares of the Company’s common stock held by the stockholder that would otherwise have been exchanged for the fractional share interest. All stock options and warrants outstanding and common stock reserved for issuance under the Company’s equity incentive plans immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by 25 and, as applicable, multiplying the exercise price by 25, as a result of the reverse stock split. All of the share numbers, share prices and exercise prices have been adjusted on a retroactive basis as if such 1-for-25 reverse stock split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse stock split. Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not identify any impairment losses for either of the three or nine months ended October 31, 2019 or 2018. Net Loss per Share Basic net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock outstanding during the period. The weighted-average shares outstanding for the three and nine months ended October 31, 2019 and 2018 excludes 7,733 shares of unvested restricted common stock. Diluted net loss per share attributable to common stockholders is calculated based on the weighted-average number of shares of the Company’s common stock outstanding and other dilutive securities outstanding during the period. As of October 31, 2019 and 2018, approximately 6,325,000 and 7,604,000 of potentially dilutive securities, respectively, were excluded from the computation of diluted net loss per share because their effect on net loss per share would be anti-dilutive. Warrant Liability The Company accounts for certain of its warrants as derivative liabilities based on provisions relating to cash settlement options. The Company recorded a liability for the fair value of the warrants at the time of issuance, and at each reporting date the warrants are revalued to the instrument’s fair value. The fair value of the warrants are estimated using the Black-Scholes pricing model. This liability is subject to fair value re-measurement until the warrants are exercised or expired, and any change in fair value is recognized as other income or expense in the condensed consolidated statements of operations and comprehensive loss. Summary of Significant Accounting Policies These unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the fiscal year ended January 31, 2019. There have been no significant changes in the Company’s significant accounting policies for the three and nine months ended October 31, 2019, except for the adoption of Accounting Standards Update 2016-02, Leases , as discussed below, as compared to the significant accounting policies described in the Annual Report on Form 10-K for the fiscal year ended January 31, 2019. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, Leases , and in July 2018, ASU No. 2018-11, Targeted Improvements , which requires entities to recognize assets and liabilities for leases with lease terms greater than twelve months. The Company adopted this standard as of February 1, 2019, and the Company’s leases are classified as operating leases and will continue to be classified as operating leases under the new accounting method. Adoption of the new standard resulted in the recording of an operating lease right-to-use asset of $1.2 million, which represents the present value of the remaining lease payments as of the date of adoption discounted using an incremental borrowing rate of 15%, and an operating lease liability of $1.3 million. The adoption did not have an impact on the Company’s condensed consolidated statement of operations and comprehensive loss or cash flows. See Note 9 for further information. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting , which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The amendment is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company adopted this update as of February 1, 2019 and the adoption did not have a material effect on its condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , which amended certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendment is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting this amendment, but does not anticipate it will have a material impact on its disclosures. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.	1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business BioPharmX Corporation (the “Company”) is incorporated under the laws of the state of Delaware and originally incorporated on August 30, 2010 in Nevada under the name Thompson Designs, Inc. The Company has one wholly-owned subsidiary, BioPharmX, Inc., a Nevada corporation. The Company is a specialty pharmaceutical company focused on the dermatology market. Its focus is to develop products that treat dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal. Its strategy is to bring new products to market by identifying optimal delivery mechanisms and/or alternative applications for United States Food and Drug Adminstration (FDA) approved or well characterized active pharmaceutical ingredients, or APIs. The Company aims to reduce the time, cost and risks typically associated with new product development by utilizing APIs with demonstrated safety profiles and, when applicable, taking advantage of the regulatory approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Section 505(b)(2) permits an applicant for a new product, such as a new or improved formulation or a new use of an approved product, to rely in part on literature and/or the FDA’s findings of safety and/or effectiveness for a similar previously-approved product. The Company’s approach is to identify the limitations of current treatment options and work to develop novel products using our proprietary HyantX™ topical drug delivery system. The Company commercially launched its iodine breast health supplement, VI 2 OLET, in December 2014. In November 2018, the Company divested the rights to develop, manufacture, market and sell its molecular iodine technology, including VI 2 OLET. This divestiture resulted in a de minimis loss, which is included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. All tangible and intangible assets related to VI 2 OLET, including but not limited to existing customer and vendor arrangements, were included in this divestiture. Since the Company’s inception, substantially all of the Company’s efforts have been devoted to developing its product candidates, including conducting preclinical and clinical trials, and providing general and administrative support for its operations. The Company has financed its operations primarily through the sale of equity and convertible notes. Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates. Accounts Receivable, net Accounts receivable are related to the sale of the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Accounts receivable were recorded net of cash discounts for prompt payment and return allowances. The allowance for doubtful accounts receivable recorded as of January 31, 2019 and 2018 was immaterial. Inventories Inventories as of January 31, 2018 were related to the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Inventories were stated at the lower of cost or net realizable value. Cost was determined using the standard cost method which approximated actual cost on a first-in, first-out basis. The Company regularly reviewed inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for inventory, which may have become obsolete or are in excess of anticipated demand or net realizable value. Fair Value of Financial Instruments Carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to their short maturities. Property and Equipmen t , net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are as follows: Estimated Description Useful Life Furniture 5 - 7 Laboratory equipment 3 - 5 Computer and equipment 3 - 5 Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not identify any impairment losses for the years ended January 31, 2019 or 2018. Warrant Liability The Company accounts for certain of its warrants as derivative liabilities based on provisions relating to cash settlement options. The Company recorded a liability for the fair value of the warrants at the time of issuance, and at each reporting date the warrants are revalued to the instrument’s fair value. The fair value of the warrants are estimated using the Black-Scholes pricing model. This liability is subject to fair value re-measurement until the warrants are exercised or expired, and any change in fair value is recognized as other income or expense in the consolidated statements of operations and comprehensive loss. Revenue Recognition Revenue is related to the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Effective February 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method. The cumulative effect of the initial application of ASC 606 of approximately $2,000 was recognized as an adjustment to accumulated deficit and a decrease to deferred revenue as of February 1, 2018. The adoption of ASC 606 did not have a material impact on the Company’s consolidated balance sheet, statement of operations and comprehensive loss and statement of cash flows for the year ended January 31, 2019. Revenue is recognized when control is transferred to the customer, which is typically upon shipment. There are no significant post-shipment obligations. Revenue is recognized at the transaction price, which includes estimates of variable consideration for reserves related to estimated product returns, pricing discounts or other concessions. These estimates are based on estimates of the amount earned or to be claimed on the related sales and are based on historical information and current contractual requirements. The Company evaluated whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No such assets existed as of January 31, 2019 or February 1, 2018. As of February 1, 2018, deferred revenue was immaterial. The Company applies the practical expedient to make adjustments for a significant financing component unnecessary if, at contract inception, the Company does not expect the period between customer payment and transfer of control of the promised goods or services to the customer to exceed one year. During the year ended January 31, 2019, the Company did not have any contracts for the sale of its products with its customers with a significant financing component. The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. During the year ended January 31, 2019, the Company expensed the incremental costs of obtaining the contract as an expense when incurred as the amortization period was one year or less. Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Cost of Good Sold Cost of goods sold is related to the iodine dietary supplement, VI 2 OLET, which was divested in November 2018. Cost of good sold includes direct costs related to the sale of VI 2 OLET, write-downs of excess and obsolete inventories and amortization of intangible assets. Shipping and Handling Costs Shipping and handling costs are expensed as incurred and are included in cost of goods sold. Research and Development Expenses Research and development expenses are expensed as incurred and consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations, product development, consulting, materials, supplies, and facilities and other overhead allocations. Advertising Expenses The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were approximately $10,000 and $29,000 for the years ended January 31, 2019 and 2018, respectively. Income Taxes The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when management estimates, based on available objective evidence, that it is more likely than not that the benefit will not be realized for the deferred tax assets. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. No interest expense was recognized during the periods presented. Stock-Based Compensation The Company recognizes stock-based compensation for equity awards on a straight-line basis over their vesting periods based on the grant date fair value. The Company estimates the fair value of stock options granted using the Black-Scholes pricing model. This model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss is the change in equity of an enterprise, except those resulting from stockholder transactions. Accordingly, comprehensive loss includes certain changes in equity that are excluded from net loss. For the years ended January 31, 2019 and 2018, the Company’s comprehensive loss is equal to its net loss. There were no components of other comprehensive loss for any of the periods presented. Net Loss Per Share Basic net loss per share attributable to common stockholders is calculated based on the weighted average number of shares of the Company’s common stock outstanding during the period. The weighted average shares outstanding for the years ended January 31, 2019 and 2018 exclude 193,333 shares of unvested restricted common stock. Diluted net loss per share attributable to common stockholders is calculated based on the weighted average number of shares of the Company’s common stock outstanding and other dilutive securities outstanding during the period. As of January 31, 2019 and 2018, approximately 182,702,000 and 215,810,000, potentially dilutive securities, respectively, were excluded from the computation of diluted loss per share because their effect on net loss per share would be anti-dilutive. Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02, Leases , and in July 2018, ASU No. 2018-11, Targeted Improvements , which requires entities to recognize assets and liabilities for leases with lease terms greater than twelve months. The new guidance also requires quantitative and qualitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company does not expect a material impact on the statement of operations and comprehensive loss or cash flows from the adoption of this standard. In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting . This amendment impacts entities that change the terms or conditions of a share-based payment award. The Company adopted this guidance as of February 1, 2018 for awards that are modified after that date, and the adoption did not have a material effect on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting , which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The amendment is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated financial statements as a result of future adoption.

GOING CONCERN_2

GOING CONCERN	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
GOING CONCERN
GOING CONCERN	2. GOING CONCERN The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and will continue to conduct operations for the foreseeable future and realize assets and discharge liabilities in the ordinary course of operations. As of October 31, 2019, the Company had cash and cash equivalents of $1.4 million and working capital of $0.3 million. The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock and the issuance of convertible notes. The Company incurred a net loss of $2.1 million and $4.4 million for the three months ended October 31, 2019 and 2018, respectively, and a net loss of $8.4 million and $13.2 million for the nine months ended October 31, 2019 and 2018, respectively. The Company had an accumulated deficit of $86.9 million as of October 31, 2019. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company has taken steps to reduce its cash outflow by reducing headcount and curtailing certain research and development activities. The Company has retained a transaction advisory firm to assist with the evaluation of strategic alternatives. Strategic alternatives that have been or are being considered include a license or sale of late-stage topical minocycline product candidates, a sale of the Company, a strategic business combination and raising additional capital. However, there can be no assurance that the strategic review process will result in any transaction or on terms which are favorable to the Company. Failure to enter into a strategic transaction or raise additional capital could have a material adverse effect on the Company’s ability to achieve its business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.	2. GOING CONCERN The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern and will continue to conduct operations for the foreseeable future and realize assets and discharge liabilities in the ordinary course of operations. As of January 31, 2019, the Company had cash and cash equivalents of $3.1 million and working capital of $1.1 million. The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock and the issuance of convertible notes. The Company incurred a net loss of $17.3 million and $16.6 million for the years ended January 31, 2019 and 2018, respectively, and had an accumulated deficit of $78.5 million as of January 31, 2019. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company continues its research and development efforts for its product candidates, which will require significant funding. If the Company is unable to obtain additional financing in the future or research and development efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses and either entering into a strategic partnership or raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available or on terms which are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, enter into a strategic partnership or reduce certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.

FAIR VALUE MEASUREMENTS_2

FAIR VALUE MEASUREMENTS	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	3. FAIR VALUE MEASUREMENTS The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. · Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. · Level 2— Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. · Level 3— Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. As of October 31, 2019 and January 31, 2019, the Company held $1.3 million and $2.5 million, respectively, in money market funds, which are classified as Level 1 within the fair value hierarchy. No unrealized gains or losses are recorded in connection with these amounts. The fair value of the warrant liability was classified as a Level 3 liability, as the Company uses unobservable inputs to value it. The table below presents the activity within Level 3 of the fair value hierarchy (in thousands): Warrant Liability Balance as of February 1, 2019 $ 11 Change in fair value of warrants (9) Balance as of April 30, 2019 2 Change in fair value of warrants (2) Balance as of July 31, 2019 and October 31, 2019 $ — The warrant liability is included in long - term liabilities on the condensed consolidated balance sheets.	4. FAIR VALUE MEASURMENTS The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. · Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. · Level 2— Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. · Le vel 3— Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. As of January 31, 2019 and 2018, the Company held $2.5 million and $7.1 million, respectively, in money market funds, which are classified as Level 1 within the fair value hierarchy. No unrealized gains or losses are recorded in connection with these amounts. The fair value of the warrant liability was classified as a Level 3 liability, as the Company uses unobservable inputs to value it. The table below presents the activity within Level 3 of the fair value hierarchy (in thousands): Warrant Liability Balance as of January 31, 2017 $ 403 Change in fair value of warrants (364) Balance as of January 31, 2018 39 Change in fair value of warrants (28) Balance as of January 31, 2019 $ 11 The warrant liability is included in long - term liabilities on the consolidated balance sheets.

BALANCE SHEET DETAILS_2

BALANCE SHEET DETAILS	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
BALANCE SHEET DETAILS
BALANCE SHEET DETAILS	4. BALANCE SHEET DETAILS October 31, January 31, 2019 2019 (in thousands) Accrued expenses and other current liabilities: Compensation $ 417 $ 371 Operating lease liability - current portion 260 — Research and development 119 399 Other 67 164 $ 863 $ 934	3. BALANCE SHEET DETAILS January 31, 2019 2018 (in thousands) Inventories: Work in process $ — $ Finished goods — Channel inventory — $ — $ 10 January 31, 2019 2018 (in thousands) Property and equipment, net: Furniture $ — $ Laboratory equipment Computer and equipment Less: accumulated depreciation $ 148 $ 109 Depreciation expense for the years ended January 31, 2019 and 2018 was approximately $62,000 and $52,000, respectively. January 31, 2019 2018 (in thousands) Accrued liabilities: Research and development $ 399 $ 404 Payroll 371 368 Legal 45 438 Purchase commitment liability — 215 Deferred revenue — 8 Other 119 170 $ 934 $ 1,603

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	5. COMMITMENTS AND CONTINGENCIES Commitments The Company is party to an agreement with a contract research organization (CRO) to conduct the Phase 2 clinical trial for BPX04, a topical antibiotic for the treatment of rosacea. The actual amounts owed under the agreement and the timing of those obligations depend on various factors, including the rate of patient enrollment, any protocol amendments and other factors relating to the clinical trial. As of October 31, 2019, all liability amounts were recorded, excluding any potential amendments to the agreement. The Company can terminate the agreement at any time and any amounts incurred through the termination date would be due to the CRO. See Note 9 for discussion regarding the Company’s operating and financing lease commitments. Legal Proceedings The Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patents or other intellectual property rights. The Company is not a party to any material legal proceeding, nor is it aware of any pending or threatened litigation that the Company believes is likely to have a material adverse effect on its business, results of operations, cash flows or financial condition should such litigation be resolved unfavorably. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts. Indemnification The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has entered into indemnification agreements with its directors, officers and certain of its medical advisors that may require the Company to indemnify its directors, officers and such medical advisors against liabilities that may arise by reason of their status or service in these roles, other than liabilities arising from willful misconduct of the individual. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such indemnifications has been recorded to date.	5. COMMITMENTS AND CONTINGENCIES Commitments The following table summarizes the Company’s commitments as of January 31, 2019 (in thousands): Fiscal years ending January 31, Total 2020 2021 2022 2023 2024 Operating lease $ 1,539 $ 280 $ 315 $ 324 $ 334 $ 286 Capital lease for laboratory equipment 47 22 22 3 — — Total $ 1,586 $ 302 $ 337 $ 327 $ 334 $ 286 On October 30, 2018, the Company signed a lease for 11,793 square feet of office and laboratory space in San Jose, California. The lease commenced in December 2018 and will terminate in December 2023. Rent expense for the years ended January 31, 2019 and 2018 was approximately $586,000 and $612,000, respectively. The Company is party to an agreement with a contract research organization (CRO) to conduct the Phase 2 clinical trial for BPX04, a topical antibiotic for the treatment of rosacea. The actual amounts owed under the agreement and the timing of those obligations depend on various factors, including the rate of patient enrollment, any protocol amendments and other factors relating to the clinical trial. As of January 31, 2019, the remaining liability under the agreement, excluding any potential amendments to the agreement, was $0.8 million. The Company can terminate the agreement at any time and any amounts incurred through the termination date would be due to the CRO. The Company recorded a capital lease obligation related to laboratory equipment in March 2018. The leased asset value was approximately $61,000 and the corresponding current and long-term liabilities were recorded in accrued liabilities and other current liabilities and long-term liabilities, respectively. Total future payments representing interest until the termination of lease are approximately $5,000. Legal Proceedings The Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patents or other intellectual property rights. The Company is not a party to any material legal proceeding, nor is it aware of any pending or threatened litigation that the Company believes is likely to have a material adverse effect on its business, results of operations, cash flows or financial condition should such litigation be resolved unfavorably. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts. Indemnification The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has entered into indemnification agreements with its directors, officers and certain of its medical advisors that may require the Company to indemnify its directors, officers and such medical advisors against liabilities that may arise by reason of their status or service in these roles, other than liabilities arising from willful misconduct of the individual. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such indemnifications has been recorded to date.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS? EQUITY	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
STOCKHOLDERS’ EQUITY
STOCKHOLDERS’ EQUITY	6. STOCKHOLDERS’ EQUITY Common Stock In March 2019, the Company issued 1,745,800 shares of common stock at a price per share of $0.09 resulting in net proceeds of $3.6 million in a registered direct offering. In May 2019, the Company entered into a Capital on Demand TM Sales Agreement (Sales Agreement) with JonesTrading Institutional Services LLC, as agent (JonesTrading), pursuant to which the Company may offer and sell, from time to time through JonesTrading, shares of the Company’s common stock, par value $0.001 per share (the Common Stock), having an aggregate offering price of up to $8.5 million. As of October 31, 2019, the Company had sold an aggregate of 4,747,812 shares of Common Stock pursuant to the terms of such Sales Agreement for aggregate net proceeds of $3.6 million. Warrants A summary of warrants outstanding as of October 31, 2019 is as follows: Total Price per Share Expiration Date Warrants related to November 2014 financing 19,762 $ 92.50 November 2019 Warrants related to June 2015 financing 4,363 $ 68.75 June 2020 Warrants related to April 2016 financing 70,581 $ 30.00 April 2021 Warrants related to September 2016 financing (1) 51,466 $ 18.75 September 2021 to March 2022 Warrants related to November 2016 financing 1,216,230 $ 8.75 November 2024 Warrants related to November 2016 financing 35,818 $10.938 November 2022 Warrants related to November 2016 financing 7,926 $ 8.25 November 2022 Warrants related to April 2017 financing 32,053 $ 22.50 October 2022 Warrants related to October 2017 financing 153,848 $ 7.50 October 2022 Warrants related to November 2017 financing 2,277,412 $ 5.00 November 2022 Warrants related to November 2018 financing (2) 1,066,670 $ 4.10 May/June 2021 4,936,129 (1) In connection with the sale of common stock in September 2016, warrants to purchase 51,466 shares of common stock were issued at an exercise price of $18.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of October 31, 2019, the fair value of the warrant liability was immaterial and was included in other long-term liabilities. (2) On November 20, 2018, the Company entered into agreements with holders of certain of its warrants to purchase common stock with an exercise price per share of $6.25 originally issued on November 24, 2017 (Existing Warrants), whereby the holders and the Company agreed that the holders would cash exercise up to 1,066,670 shares of common stock underlying such Existing Warrants at a reduced price of $3.50, and the Company would issue new warrants to such holders to purchase up to an aggregate of 1,066,670 shares of common stock (New Warrants). The New Warrants are exercisable after the six-month anniversary of their issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $4.10. The Company recorded a charge for the incremental fair value of approximately $874,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.51%, contractual term of 6 months, expected volatility of 78.4% and a dividend rate of 0%. Equity Incentive Plan On July 5, 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan), which permits the Company to grant equity awards to directors, officers, employees and consultants. In connection with the adoption of the 2016 Plan, the Company ceased to grant equity awards under its 2014 Equity Incentive Plan (2014 Plan), which was adopted on January 23, 2014. All grants and awards under the 2014 Plan, including stock options previously issued under BioPharmX, Inc.’s 2011 Equity Incentive Plan that were substituted with stock options issued under the 2014 Plan, remain in effect in accordance with their terms. Stock options generally vest in one to four years and expire ten years from the date of grant. In March 2017, the 2016 Plan was amended and the shares reserved for issuance were increased by 800,000 shares to a total of 960,000 shares of common stock. In August 2018, the 2016 Plan was amended and the shares reserved for issuance were increased by 2,000,000 shares to a total of 2,960,000 shares of common stock. The 2014 Plan and 2016 Plan are referred to collectively as the “Plans.” The following table summarizes the Company’s stock option awards under the Plans: Weighted Average Remaining Aggregate Available for Exercise Contractual Intrinsic Grant Shares Prices Life Value (in thousands) Balance as of February 1, 2019 2,107,575 917,945 $ $ 23 Granted (16,720) 16,720 $ 3.21 Exercised — (1,667) $ 2.50 Canceled and expired under the 2014 Plan — $ 28.27 Canceled under the 2016 Plan 69,180 (69,180) $ 8.84 Balance as of April 30, 2019 2,160,035 $ 8.27 8.35 $ — Granted (877,100) $ 0.80 Canceled and expired under the 2014 Plan — $ 13.06 Canceled under the 2016 Plan 224,654 (224,654) $ 4.18 Balance as of July 31, 2019 1,507,589 $ 4.44 8.62 $ — Canceled and expired under the 2014 Plan — $ 28.13 Canceled under the 2016 Plan $ 8.54 Balance as of October 31, 2019 $ 3.93 8.95 $ — Vested and exercisable $ 7.56 8.05 $ — Vested and expected to vest $ 4.26 8.87 $ — Inducement Grants The Company has also awarded inducement option grants to purchase common stock to new employees outside of the 2016 Plan as permitted under Section 711(a) of the NYSE American Company Guide. Such options vest at the rate of 25% of the shares on the first anniversary of the commencement of such employee’s employment with the Company, and then one forty-eighth (1/48) of the shares monthly thereafter subject to such employee’s continued service. The following table summarizes the Company’s inducement grant stock option awards: Weighted Average Remaining Exercise Contractual Aggregate Shares Prices Life Intrinsic Value (in thousands) Balance as of February 1, 2019 31,000 $ $ — Canceled (6,000) $ Balance as of April 30, 2019 25,000 $ $ — Canceled (750) $ Balance as of July 31, 2019 24,250 $ $ — Canceled (8,250) $ Balance as of October 31, 2019 16,000 $ $ — Vested and exercisable 6,667 $ $ — Vested and expected to vest 13,819 $ $ — The following table summarizes significant ranges of outstanding and exercisable options as of October 31, 2019: Options Outstanding Options Vested and Exercisable Weighted Average Weighted Weighted Remaining Average Number Average Number Contractual Exercise Vested and Exercise Range of Exercise Prices Outstanding Life (in Years) Prices Exercisable Prices $0.44 - $0.84 $ $ $0.85 - $4.00 $ $ $4.01 - $10.50 $ $ $10.51- $18.50 $ $ $18.51 - $28.50 $ $ $28.51 - $75.00 $ 14,354 $ 51.19 $ $ There were no stock options exercised during the three months ended October 31, 2019. The total intrinsic value of stock options exercised was less than $1,000 during the nine months ended October 31, 2019. The total intrinsic value of stock options exercised during the three and nine months ended October 31, 2018 was approximately $24,000 and $26,000, respectively.	6. CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY Common Stock In April 2017, the Company issued 6,410,258 shares of common stock at a price per share of $0.78 resulting in net proceeds of $4.4 million and warrants to purchase 3,365,385 shares of common stock at an exercise price of $0.90 in a registered direct offering. In July 2017, the Company issued 5,500,000 shares of common stock at a price per share of $0.36 resulting in net proceeds of $1.9 million in a registered direct offering. In November 2017, the Company issued 45,275,000 shares of common stock, pre-funded warrants to purchase 28,225,000 shares of common stock, and accompanying Series A common warrants to purchase 73,500,000 shares of common stock (“Series A Warrants”), and accompanying Series B common warrants to purchase 73,500,000 shares of common stock (“Series B Warrants”), resulting in net proceeds of $9.7 million. Each share of common stock and pre-funded warrant was sold together with a Series A Warrant to purchase one share of common stock and a Series B Warrant to purchase one share of common stock. The public offering price was $0.15 per share of common stock and accompanying Series A Warrant and Series B Warrant and $0.1490 per pre-funded warrant and accompanying Series A Warrant and Series B Warrant. The pre-funded warrants were issued and sold to purchasers in lieu of shares of common stock that would otherwise result in the purchaser's beneficial ownership exceeding 4.99% (or at the election of the purchaser, 9.99%) of the Company’s outstanding Common Stock immediately following the closing of the offering. The pre-funded warrants have a nominal exercise price of $0.001 per share and have been fully exercised. The Series A Warrants have an exercise price of $0.20 per share, are exercisable immediately and expire five years from the date of issuance. The Series B Warrants have an exercise price of $0.25 per share, are exercisable immediately and expire on the earlier of (1) the twenty-first trading day after the Company issues a press release announcing it has entered into a strategic licensing, collaboration, partnership or similar agreement for the commitment to fund its Phase 3 trials for BPX01, and (2) the eighteen month anniversary of issuance. Series A Convertible Preferred Stock Pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on November 22, 2016, 10,000 shares of Series A convertible preferred stock were designated. In November 2016, the Company issued 1,515 shares of Series A convertible preferred stock (Preferred Stock), which included warrants to purchase 3,246,429 shares of common stock. The Preferred Stock had a purchase price of $1,000 per share and was convertible into common stock at a conversion rate of $0.35 per share. The Preferred Stock contained a beneficial conversion feature valued at $0.1 million, which was recorded as a deemed dividend at the time of issuance, which was considered to be the earliest time of conversion. In January 2018, the Preferred Stock was converted into 4,328,571 shares of common stock. Pursuant to the Certificate of Elimination filed with the Secretary of State of the State of Delaware on March 6, 2018, all shares of Series A convertible preferred stock previously designated were returned to the status of authorized but unissued shares of preferred stock, without designation as to series or rights, preferences, privileges or limitations. Warrants A summary of warrants outstanding as of January 31, 2019 is as follows: Total Price per Share Expiration Date Warrants related to January 2014 agreement 289,505 $ 1.85 May 2019 Warrants related to May 2014 agreement 316,395 $2.035 May 2019 Warrants related to April to November 2014 financing 1,661,055 $ 3.70 April 2019 - November 2019 Warrants related to June 2015 financing 109,091 $ 2.75 June 2020 Warrants related to April 2016 financing 1,952,000 $ 1.20 April 2021 Warrants related to September 2016 financing (1) 1,286,501 $ 0.75 September 2021 to March 2022 Warrants related to November 2016 financing 30,406,061 $ 0.35 November 2022 to November 2024 Warrants related to November 2016 financing 895,450 $ 0.44 November 2022 Warrants related to November 2016 financing 198,214 $ 0.33 November 2022 Warrants related to April 2017 financing 801,282 $ 0.90 October 2022 Warrants related to October 2017 financing (2) 3,846,152 $ 0.30 October 2022 Warrants related to November 2017 financing 56,935,191 $ 0.20 November 2022 Warrants related to November 2017 financing (3) 33,422,061 $ 0.25 May 2019 Warrants related to November 2018 financing (3) 26,666,666 $0.164 May/June 2021 (1) In connection with the sale of common stock in September 2016, warrants to purchase 1,286,501 shares of common stock were issued at an exercise price of $0.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of January 31, 2019, the fair value of the warrant liability was approximately $11,000 and was included as a long-term liability. (2) On October 23, 2017, the Company entered into agreements with certain of these warrant holders to permit their immediate exercise of 2,564,103 shares of common stock underlying the warrants at an exercise price per share of $0.24. The Company recorded a charge for the incremental fair value of approximately $151,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.03%, contractual term of 5 years, expected volatility of 83.9% and a dividend rate of 0%. In addition, these warrant holders were issued new warrants to purchase up to an aggregate of 3,846,152 shares of common stock at an exercise price per share of $0.30. (3) On November 20, 2018, the Company entered into agreements with holders of certain of its warrants to purchase common stock with an exercise price per share of $0.25 originally issued on November 24, 2017 (Existing Warrants), whereby the holders and the Company agreed that the holders would cash exercise 26,666,666 shares of common stock underlying such Existing Warrants at a reduced price of $0.14, and the Company would issue new warrants to such holders to purchase up to an aggregate of 26,666,666 shares of common stock (New Warrants). The New Warrants are exercisable after the six-month anniversary of their issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $0.164. The Company recorded a charge for the incremental fair value of approximately $874,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.51%, contractual term of 6 months, expected volatility of 78.4% and a dividend rate of 0%. Equity Incentive Plan On July 5, 2016, the Company adopted the 2016 Equity Incentive Plan (“2016 Plan”), which permits the Company to grant equity awards to directors, officers, employees and consultants. In connection with the adoption of the 2016 Plan, the Company ceased to grant equity awards under its 2014 Equity Incentive Plan (“2014 Plan”), which was adopted on January 23, 2014. All grants and awards under the 2014 Plan, including stock options previously issued under BioPharmX, Inc.’s 2011 Equity Incentive Plan that were substituted with stock options issued under the 2014 Plan, remain in effect in accordance with their terms. Stock options generally vest in one to four years and expire ten years from the date of grant. In March 2017, the 2016 Plan was amended and the shares reserved for issuance was increased by 20,000,000 shares to a total of 24,000,000 shares. In August 2018, the 2016 Plan was amended and the shares reserved for issuance were increased by 50,000,000 shares to a total of 74,000,000 shares of common stock. The 2014 Plan and 2016 Plan are referred to collectively as the “Plans.” The following table summarizes the Company’s stock option activities under the Plans: Weighted Average Remaining Aggregate Available for Exercise Contractual Intrinsic Grant Shares Prices Life Value (in thousands) Balance as of February 1, 2017 252,379 6,465,829 $ $ 238 Shares authorized for issuance 20,000,000 — Granted (18,553,000) 18,553,000 $ Exercised — (40,000) $ Canceled and returned to the 2016 Plan 185,499 (185,499) $ Canceled subsequent to termination of the 2014 Plan — (68,667) $ Balance as of January 31, 2018 1,884,878 24,724,663 $ $ 304 Shares authorized for issuance 50,000,000 — Granted (10,444,000) 10,444,000 $ Exercised — (278,196) $ Canceled and returned to the 2016 Plan 11,262,538 (11,262,538) $ Canceled subsequent to termination of the 2014 Plan — (680,060) $ Balance as of January 31, 2019 52,703,416 22,947,869 $ $ 23 Vested and exercisable 9,257,545 $ $ 13 Vested and expected to vest 21,836,056 $ $ 22 Inducement Grants The Company has also awarded inducement option grants to purchase common stock to new employees outside of the 2016 Plan as permitted under Section 711(a) of the NYSE American Company Guide. Such options vest at the rate of 25% of the shares on the first anniversary of the commencement of such employee’s employment with the Company, and then one forty-eighth (1/48) of the shares monthly thereafter subject to such employee’s continued service. The following table summarizes the Company’s inducement grant stock option activities: Weighted Average Remaining Exercise Contractual Aggregate Shares Prices Life Intrinsic Value (in thousands) Balance as of February 1, 2017 and 2018 660,000 $ $ — Granted 400,000 $ Canceled (285,000) $ Balance as of January 31, 2019 775,000 $ $ — Vested and exercisable 332,812 $ $ — Vested and expected to vest 747,437 $ $ — The following table summarizes significant ranges of outstanding and exercisable options as of January 31, 2019: Options Outstanding Options Vested and Exercisable Weighted Average Weighted Weighted Remaining Average Number Average Number Contractual Exercise Vested and Exercise Range of Exercise Prices Outstanding Life (in Years) Prices Exercisable Prices $0.10 - $0.16 $ $ $0.17 - $0.35 $ $ $0.36 - $0.65 $ $ $0.66 - $1.14 $ $ $1.15 - $3.00 $ 1,003,748 $ 1.80 $ $ The total intrinsic value of stock options exercised during the years ended January 31, 2019 and 2018 was approximately $26,000 and $4,000, respectively. During the year ended January 31, 2019, certain stock options were exercised pursuant to net exercise provisions, resulting in 138,157 shares of common stock retired in exchange of the total exercise price. The weighted average grant date fair values of the stock options granted during the years ended January 31, 2019 and 2018 was $0.12 and $0.21, respectively.

STOCK-BASED COMPENSATION_2

STOCK-BASED COMPENSATION	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION	7. STOCK-BASED COMPENSATION The following table summarizes the stock-based compensation expenses included in the condensed consolidated statement of operations and comprehensive loss (in thousands): For the three months ended For the nine months ended October 31, October 31, 2019 2018 2019 2018 Research and development $ 30 $ 166 $ 218 $ 525 Sales and marketing 12 114 45 355 General and administrative 187 438 334 877 Total $ 229 $ 718 $ 597 $ 1,757 The Company estimates the fair value of stock options granted using the Black-Scholes pricing model. This model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. For employee grants, the fair value is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. As of October 31, 2019, total compensation costs related to unvested, but not yet recognized, stock-based awards was $1.0 million, net of estimated forfeitures. This cost will be amortized on a straight-line basis over a weighted average remaining period of 2.3 years and will be adjusted for subsequent changes in estimated forfeitures. Valuation Assumptions There were no stock options granted during the three months ended October 31, 2019. During the nine months ended October 31, 2019, the weighted average grant date fair value of stock options granted was $0.44 per share. The following assumptions were used to calculate the estimated fair value of awards granted for the periods ended: For the three months ended For the nine months ended October 31, October 31, 2019 2018 2019 2018 Expected volatility — 78.8% - 91.0% 68.3% - 70.8% 78.8% - 91.0% Expected term in years — 4.0 - 8.6 4.0 - 8.6 Risk-free interest rate — 2.72% - 3.10% 1.88% - 2.51% 2.72% - 3.10% Expected dividend yield — — — — Expected Term The expected term represents the period that the Company’s stock-based awards are expected to be outstanding. For awards granted subject only to service vesting requirements, the Company utilizes the simplified method for estimating the expected term of the stock-based award, instead of historical exercise data. Expected Volatility The Company uses the historical volatility of the price of shares of common stock of selected public companies, including the Company’s stock price, in the biotechnology sector due to its limited trading history. Risk-Free Interest Rate The Company bases the risk-free interest rate used in the Black-Scholes pricing model upon the implied yield curve currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term used as the assumption in the model. Expected Dividend The Company has never paid dividends on its shares of common stock and currently does not intend to do so and, accordingly, the dividend yield percentage is zero for all periods.	7. STOCK-BASED COMPENSATION The following table summarizes the stock-based compensation expenses included in the statements of operations and comprehensive loss (in thousands): Year ended January 31, 2019 2018 Research and development $ 654 $ 545 Sales and marketing 414 393 General and administrative 993 949 Total $ 2,061 $ 1,887 The Company estimates the fair value of stock options granted using the Black-Scholes pricing model. This model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. For employee grants, the fair value is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. As of January 31, 2019, total compensation costs related to unvested, but not yet recognized, stock-based awards was $2.0 million, net of estimated forfeitures. This cost will be amortized on a straight-line basis over a weighted average remaining period of 2.72 years and will be adjusted for subsequent changes in estimated forfeitures. Valuation Assumptions The following assumptions were used to calculate the estimated fair value of awards granted: Year ended January 31, 2019 2018 Expected volatility 78.8% - 91.0% 83.9% - 96.8% Expected term in years 4.0 6.0 - 9.39 Risk-free interest rate 2.43% - 2.98% 1.80% - 2.70% Expected dividend yield — — Expected Term The expected term represents the period that the Company’s stock-based awards are expected to be outstanding. For awards granted subject only to service vesting requirements, the Company utilizes the simplified method for estimating the expected term of the stock-based award, instead of historical exercise data. Expected Volatility The Company uses the historical volatility of the price of shares of common stock of selected public companies, including the Company’s stock price, in the biotechnology sector due to its limited trading history. Risk-Free Interest Rate The Company bases the risk-free interest rate used in the Black-Scholes pricing model upon the implied yield curve currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term used as the assumption in the model. Expected Dividend The Company has never paid dividends on its common shares and currently does not intend to do so and, accordingly, the dividend yield percentage is zero for all periods.

INCOME TAXES_2

INCOME TAXES	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
INCOME TAXES
INCOME TAXES	8. INCOME TAXES The Company evaluates its ability to recover deferred tax assets, in full or in part, by considering all available positive and negative evidence, including past operating results and its forecast of future taxable income on a jurisdictional basis. The Company bases its estimate of current and deferred taxes on the tax laws and rates that are currently in effect in the appropriate jurisdiction. Changes in laws or rates may affect the tax provision as well as the amount of deferred tax assets or liabilities. Current tax laws impose substantial restrictions on the utilization of net operating loss and credit carry-forwards in the event of an “ownership change,” as defined by the Internal Revenue Code. If there should be an ownership change, the Company’s ability to utilize its carry-forwards could be limited. As of October 31, 2019 and January 31, 2019, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions. The 2010 to 2019 tax years remain open for examination by the federal and state authorities.	9. INCOME TAXES No federal income taxes were paid during the years ended January 31, 2019 and 2018 due to the Company’s net losses. The provision of income taxes consist of state minimum income taxes. As of January 31, 2019, the Company had available federal net operating loss (“NOL”) carryforwards of approximately $68.6 million which will begin to expire in 2030 and California state NOL carryforwards of approximately $62.4 million which will begin to expire in 2033. As of January 31, 2019 and 2018, the net deferred tax assets of approximately $21.1 million and $16.3 million, respectively, generated primarily by NOL carryforwards, have been fully reserved due to the uncertainty surrounding the realization of such benefits. The net valuation allowance increased by approximately $4.9 million and $1.0 million during the years ended January 31, 2019 and 2018, respectively. Current tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an “ownership change,” as defined by the Internal Revenue Code. If there should be an ownership change, the Company’s ability to utilize its carryforwards could be limited. Significant components of the Company’s deferred tax assets were as follows (in thousands): January 31, Deferred tax assets: 2019 2018 Net operating loss carryforwards $ 18,769 $ 14,314 Stock-based compensation expense 1,163 831 Tax credit carryforwards 1,022 735 Other 160 377 Total deferred tax assets 21,114 16,257 Less: valuation allowance (21,114) (16,257) Net deferred tax assets $ — $ — A reconciliation of income taxes provided at the federal statutory rate (21% in 2019) to the actual income tax provision was as follows (in thousands): Year ended January 31, 2019 2018 Income tax benefit computed at U.S. statutory rate $ (3,624) $ (5,477) State income tax (net of federal benefit) (1,478) (1,150) Change in federal rate from 34% to 21% — 7,662 Change in valuation allowance 4,857 (1,039) Research and development credits (158) (129) Other 405 135 Provision for income taxes $ 2 $ 2 As of January 31, 2019 and 2018, the Company did not have any material unrecognized tax benefits. The tax years from 2010 to 2019 remain open for examination by the federal and state authorities.

LEASES

LEASES	9 Months Ended
	Oct. 31, 2019
LEASES
LEASES	9. LEASES On October 30, 2018, the Company signed a lease for 11,793 square feet of office and laboratory space in San Jose, California. The lease commenced in December 2018 and will terminate in December 2023. The lease requires payment of maintenance, utilities, taxes, insurance and other operating expenses associated with the leased space. Effective February 1, 2019, the Company adopted ASU No. 2016-02, Leases , as amended, which resulted in the recording of an operating lease right-to-use asset of $1.2 million and corresponding short-term and long-term liabilities of $0.3 million and $1.0 million, respectively. The right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease payments. The Company has an option to extend the lease for an additional 36 months, but, as the renewal is not reasonably certain, the Company has not included this renewal option in its accounting for the lease. Lease expense is recognized on a straight-line basis over the lease term and was approximately $93,000 and $160,000 for the three months ended October 31, 2019 and 2018, respectively, and approximately $278,000 and $480,000 for the nine months ended October 31, 2019 and 2018, respectively. Cash paid for amounts included in the measurement of operating lease liability for the three and nine months ended October 31, 2019 was approximately $91,000 and $246,000, respectively, and was included in net cash used in operating activities in the statement of cash flows. The future minimum payments under the Company’s operating lease as of October 31, 2019 are as follows (in thousands): Operating Lease Fiscal years ending January 31, 2020 $ 92 2021 372 2022 382 2023 392 2024 334 Total future minimum lease payments 1,572 Less: present value discount (486) Present value of operating lease liabilities $ 1,086 The Company recorded financing leases related to laboratory equipment in May 2019 and March 2018. The leased asset values were approximately $54,000 and $61,000, respectively, and the corresponding current and long-term liabilities were recorded in accrued expenses and other current liabilities and other long-term liabilities, respectively. Total future payments representing interest until the termination of leases were approximately $7,000 as of October 31, 2019. The following table summarizes the Company’s financing lease commitment as of October 31, 2019 (in thousands): Financing Leases Fiscal years ending January 31, 2020 $ 11 2021 43 2022 22 2023 5 Total $ 81

DESCRIPTION OF BUSINESS AND S_9

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended January 31, 2019, filed on March 14, 2019. The condensed consolidated balance sheet as of January 31, 2019, included herein, was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared on the same basis as the audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s statement of financial position as of October 31, 2019 and January 31, 2019, and the Company’s results of operations for the three and nine months ended October 31, 2019 and 2018 and cash flows for the nine months ended October 31, 2019 and 2018. The results for the three and nine months ended October 31, 2019 are not necessarily indicative of the results to be expected for the year ending January 31, 2020 or any future period.	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation. Accounts receivable have been included in prepaid expenses and other current assets in the condensed consolidated balance sheets. The amount for the prior period has been reclassified to be consistent with the current year presentation and has no impact on previously reported total assets, total stockholders’ equity or net loss.
Reverse Stock Split	Reverse Stock Split On April 25, 2019, the Company effected a 1-for-25 reverse stock split of its common stock. As a result of the reverse stock split, every twenty-five shares of the Company’s pre-reverse split outstanding common stock was combined and reclassified into one share of common stock. Par value per share remained unchanged at $0.001 per share. Proportionate voting rights and other rights of common stockholders were not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split; stockholders who would otherwise hold a fractional share of common stock received cash in an amount equal to the product obtained by multiplying (i) the closing price of the Company’s common stock on the last trading day prior to the effective date of the reverse stock split, by (ii) the number of shares of the Company’s common stock held by the stockholder that would otherwise have been exchanged for the fractional share interest. All stock options and warrants outstanding and common stock reserved for issuance under the Company’s equity incentive plans immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by 25 and, as applicable, multiplying the exercise price by 25, as a result of the reverse stock split. All of the share numbers, share prices and exercise prices have been adjusted on a retroactive basis as if such 1-for-25 reverse stock split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse stock split.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not identify any impairment losses for either of the three or nine months ended October 31, 2019 or 2018.	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not identify any impairment losses for the years ended January 31, 2019 or 2018.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock outstanding during the period. The weighted-average shares outstanding for the three and nine months ended October 31, 2019 and 2018 excludes 7,733 shares of unvested restricted common stock. Diluted net loss per share attributable to common stockholders is calculated based on the weighted-average number of shares of the Company’s common stock outstanding and other dilutive securities outstanding during the period. As of October 31, 2019 and 2018, approximately 6,325,000 and 7,604,000 of potentially dilutive securities, respectively, were excluded from the computation of diluted net loss per share because their effect on net loss per share would be anti-dilutive.	Net Loss Per Share Basic net loss per share attributable to common stockholders is calculated based on the weighted average number of shares of the Company’s common stock outstanding during the period. The weighted average shares outstanding for the years ended January 31, 2019 and 2018 exclude 193,333 shares of unvested restricted common stock. Diluted net loss per share attributable to common stockholders is calculated based on the weighted average number of shares of the Company’s common stock outstanding and other dilutive securities outstanding during the period. As of January 31, 2019 and 2018, approximately 182,702,000 and 215,810,000, potentially dilutive securities, respectively, were excluded from the computation of diluted loss per share because their effect on net loss per share would be anti-dilutive.
Warrant Liability	Warrant Liability The Company accounts for certain of its warrants as derivative liabilities based on provisions relating to cash settlement options. The Company recorded a liability for the fair value of the warrants at the time of issuance, and at each reporting date the warrants are revalued to the instrument’s fair value. The fair value of the warrants are estimated using the Black-Scholes pricing model. This liability is subject to fair value re-measurement until the warrants are exercised or expired, and any change in fair value is recognized as other income or expense in the condensed consolidated statements of operations and comprehensive loss.	Warrant Liability The Company accounts for certain of its warrants as derivative liabilities based on provisions relating to cash settlement options. The Company recorded a liability for the fair value of the warrants at the time of issuance, and at each reporting date the warrants are revalued to the instrument’s fair value. The fair value of the warrants are estimated using the Black-Scholes pricing model. This liability is subject to fair value re-measurement until the warrants are exercised or expired, and any change in fair value is recognized as other income or expense in the consolidated statements of operations and comprehensive loss.
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies These unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the fiscal year ended January 31, 2019. There have been no significant changes in the Company’s significant accounting policies for the three and nine months ended October 31, 2019, except for the adoption of Accounting Standards Update 2016-02, Leases , as discussed below, as compared to the significant accounting policies described in the Annual Report on Form 10-K for the fiscal year ended January 31, 2019.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, Leases , and in July 2018, ASU No. 2018-11, Targeted Improvements , which requires entities to recognize assets and liabilities for leases with lease terms greater than twelve months. The Company adopted this standard as of February 1, 2019, and the Company’s leases are classified as operating leases and will continue to be classified as operating leases under the new accounting method. Adoption of the new standard resulted in the recording of an operating lease right-to-use asset of $1.2 million, which represents the present value of the remaining lease payments as of the date of adoption discounted using an incremental borrowing rate of 15%, and an operating lease liability of $1.3 million. The adoption did not have an impact on the Company’s condensed consolidated statement of operations and comprehensive loss or cash flows. See Note 9 for further information. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting , which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The amendment is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company adopted this update as of February 1, 2019 and the adoption did not have a material effect on its condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , which amended certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendment is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting this amendment, but does not anticipate it will have a material impact on its disclosures. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.	Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02, Leases , and in July 2018, ASU No. 2018-11, Targeted Improvements , which requires entities to recognize assets and liabilities for leases with lease terms greater than twelve months. The new guidance also requires quantitative and qualitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company does not expect a material impact on the statement of operations and comprehensive loss or cash flows from the adoption of this standard. In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting . This amendment impacts entities that change the terms or conditions of a share-based payment award. The Company adopted this guidance as of February 1, 2018 for awards that are modified after that date, and the adoption did not have a material effect on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting , which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The amendment is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated financial statements as a result of future adoption.

FAIR VALUE MEASUREMENTS (Tabl_2

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
FAIR VALUE MEASUREMENTS
Schedule of Fair Value of Warrant Liability Classified as Level 3 Liabilities	The table below presents the activity within Level 3 of the fair value hierarchy (in thousands): Warrant Liability Balance as of February 1, 2019 $ 11 Change in fair value of warrants (9) Balance as of April 30, 2019 2 Change in fair value of warrants (2) Balance as of July 31, 2019 and October 31, 2019 $ —	The fair value of the warrant liability was classified as a Level 3 liability, as the Company uses unobservable inputs to value it. The table below presents the activity within Level 3 of the fair value hierarchy (in thousands): Warrant Liability Balance as of January 31, 2017 $ 403 Change in fair value of warrants (364) Balance as of January 31, 2018 39 Change in fair value of warrants (28) Balance as of January 31, 2019 $ 11

BALANCE SHEET DETAILS (Tables_2

BALANCE SHEET DETAILS (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
BALANCE SHEET DETAILS
Schedule accrued expenses and other current liabilities	October 31, January 31, 2019 2019 (in thousands) Accrued expenses and other current liabilities: Compensation $ 417 $ 371 Operating lease liability - current portion 260 — Research and development 119 399 Other 67 164 $ 863 $ 934	January 31, 2019 2018 (in thousands) Accrued liabilities: Research and development $ 399 $ 404 Payroll 371 368 Legal 45 438 Purchase commitment liability — 215 Deferred revenue — 8 Other 119 170 $ 934 $ 1,603

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS? EQUITY (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Schedule of outstanding warrants	A summary of warrants outstanding as of October 31, 2019 is as follows: Total Price per Share Expiration Date Warrants related to November 2014 financing 19,762 $ 92.50 November 2019 Warrants related to June 2015 financing 4,363 $ 68.75 June 2020 Warrants related to April 2016 financing 70,581 $ 30.00 April 2021 Warrants related to September 2016 financing (1) 51,466 $ 18.75 September 2021 to March 2022 Warrants related to November 2016 financing 1,216,230 $ 8.75 November 2024 Warrants related to November 2016 financing 35,818 $10.938 November 2022 Warrants related to November 2016 financing 7,926 $ 8.25 November 2022 Warrants related to April 2017 financing 32,053 $ 22.50 October 2022 Warrants related to October 2017 financing 153,848 $ 7.50 October 2022 Warrants related to November 2017 financing 2,277,412 $ 5.00 November 2022 Warrants related to November 2018 financing (2) 1,066,670 $ 4.10 May/June 2021 4,936,129 (1) In connection with the sale of common stock in September 2016, warrants to purchase 51,466 shares of common stock were issued at an exercise price of $18.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of October 31, 2019, the fair value of the warrant liability was immaterial and was included in other long-term liabilities. (2) On November 20, 2018, the Company entered into agreements with holders of certain of its warrants to purchase common stock with an exercise price per share of $6.25 originally issued on November 24, 2017 (Existing Warrants), whereby the holders and the Company agreed that the holders would cash exercise up to 1,066,670 shares of common stock underlying such Existing Warrants at a reduced price of $3.50, and the Company would issue new warrants to such holders to purchase up to an aggregate of 1,066,670 shares of common stock (New Warrants). The New Warrants are exercisable after the six-month anniversary of their issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $4.10. The Company recorded a charge for the incremental fair value of approximately $874,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.51%, contractual term of 6 months, expected volatility of 78.4% and a dividend rate of 0%.	A summary of warrants outstanding as of January 31, 2019 is as follows: Total Price per Share Expiration Date Warrants related to January 2014 agreement 289,505 $ 1.85 May 2019 Warrants related to May 2014 agreement 316,395 $2.035 May 2019 Warrants related to April to November 2014 financing 1,661,055 $ 3.70 April 2019 - November 2019 Warrants related to June 2015 financing 109,091 $ 2.75 June 2020 Warrants related to April 2016 financing 1,952,000 $ 1.20 April 2021 Warrants related to September 2016 financing (1) 1,286,501 $ 0.75 September 2021 to March 2022 Warrants related to November 2016 financing 30,406,061 $ 0.35 November 2022 to November 2024 Warrants related to November 2016 financing 895,450 $ 0.44 November 2022 Warrants related to November 2016 financing 198,214 $ 0.33 November 2022 Warrants related to April 2017 financing 801,282 $ 0.90 October 2022 Warrants related to October 2017 financing (2) 3,846,152 $ 0.30 October 2022 Warrants related to November 2017 financing 56,935,191 $ 0.20 November 2022 Warrants related to November 2017 financing (3) 33,422,061 $ 0.25 May 2019 Warrants related to November 2018 financing (3) 26,666,666 $0.164 May/June 2021 (1) In connection with the sale of common stock in September 2016, warrants to purchase 1,286,501 shares of common stock were issued at an exercise price of $0.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of January 31, 2019, the fair value of the warrant liability was approximately $11,000 and was included as a long-term liability. (2) On October 23, 2017, the Company entered into agreements with certain of these warrant holders to permit their immediate exercise of 2,564,103 shares of common stock underlying the warrants at an exercise price per share of $0.24. The Company recorded a charge for the incremental fair value of approximately $151,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.03%, contractual term of 5 years, expected volatility of 83.9% and a dividend rate of 0%. In addition, these warrant holders were issued new warrants to purchase up to an aggregate of 3,846,152 shares of common stock at an exercise price per share of $0.30. (3) On November 20, 2018, the Company entered into agreements with holders of certain of its warrants to purchase common stock with an exercise price per share of $0.25 originally issued on November 24, 2017 (Existing Warrants), whereby the holders and the Company agreed that the holders would cash exercise 26,666,666 shares of common stock underlying such Existing Warrants at a reduced price of $0.14, and the Company would issue new warrants to such holders to purchase up to an aggregate of 26,666,666 shares of common stock (New Warrants). The New Warrants are exercisable after the six-month anniversary of their issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $0.164. The Company recorded a charge for the incremental fair value of approximately $874,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.51%, contractual term of 6 months, expected volatility of 78.4% and a dividend rate of 0%.
Schedule of significant ranges of outstanding and exercisable options	Options Outstanding Options Vested and Exercisable Weighted Average Weighted Weighted Remaining Average Number Average Number Contractual Exercise Vested and Exercise Range of Exercise Prices Outstanding Life (in Years) Prices Exercisable Prices $0.44 - $0.84 $ $ $0.85 - $4.00 $ $ $4.01 - $10.50 $ $ $10.51- $18.50 $ $ $18.51 - $28.50 $ $ $28.51 - $75.00 $ 14,354 $ 51.19 $ $	Options Outstanding Options Vested and Exercisable Weighted Average Weighted Weighted Remaining Average Number Average Number Contractual Exercise Vested and Exercise Range of Exercise Prices Outstanding Life (in Years) Prices Exercisable Prices $0.10 - $0.16 $ $ $0.17 - $0.35 $ $ $0.36 - $0.65 $ $ $0.66 - $1.14 $ $ $1.15 - $3.00 $ 1,003,748 $ 1.80 $ $
The Plans
Stock option plan activity	Weighted Average Remaining Aggregate Available for Exercise Contractual Intrinsic Grant Shares Prices Life Value (in thousands) Balance as of February 1, 2019 2,107,575 917,945 $ $ 23 Granted (16,720) 16,720 $ 3.21 Exercised — (1,667) $ 2.50 Canceled and expired under the 2014 Plan — $ 28.27 Canceled under the 2016 Plan 69,180 (69,180) $ 8.84 Balance as of April 30, 2019 2,160,035 $ 8.27 8.35 $ — Granted (877,100) $ 0.80 Canceled and expired under the 2014 Plan — $ 13.06 Canceled under the 2016 Plan 224,654 (224,654) $ 4.18 Balance as of July 31, 2019 1,507,589 $ 4.44 8.62 $ — Canceled and expired under the 2014 Plan — $ 28.13 Canceled under the 2016 Plan $ 8.54 Balance as of October 31, 2019 $ 3.93 8.95 $ — Vested and exercisable $ 7.56 8.05 $ — Vested and expected to vest $ 4.26 8.87 $ —
Outside of the 2016 Equity Incentive Plan
Stock option plan activity	Weighted Average Remaining Exercise Contractual Aggregate Shares Prices Life Intrinsic Value (in thousands) Balance as of February 1, 2019 31,000 $ $ — Canceled (6,000) $ Balance as of April 30, 2019 25,000 $ $ — Canceled (750) $ Balance as of July 31, 2019 24,250 $ $ — Canceled (8,250) $ Balance as of October 31, 2019 16,000 $ $ — Vested and exercisable 6,667 $ $ — Vested and expected to vest 13,819 $ $ —	Weighted Average Remaining Exercise Contractual Aggregate Shares Prices Life Intrinsic Value (in thousands) Balance as of February 1, 2017 and 2018 660,000 $ $ — Granted 400,000 $ Canceled (285,000) $ Balance as of January 31, 2019 775,000 $ $ — Vested and exercisable 332,812 $ $ — Vested and expected to vest 747,437 $ $ —

STOCK-BASED COMPENSATION (Tab_2

STOCK-BASED COMPENSATION (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
STOCK-BASED COMPENSATION
Summary of stock based compensation expense	The following table summarizes the stock-based compensation expenses included in the condensed consolidated statement of operations and comprehensive loss (in thousands): For the three months ended For the nine months ended October 31, October 31, 2019 2018 2019 2018 Research and development $ 30 $ 166 $ 218 $ 525 Sales and marketing 12 114 45 355 General and administrative 187 438 334 877 Total $ 229 $ 718 $ 597 $ 1,757	The following table summarizes the stock-based compensation expenses included in the statements of operations and comprehensive loss (in thousands): Year ended January 31, 2019 2018 Research and development $ 654 $ 545 Sales and marketing 414 393 General and administrative 993 949 Total $ 2,061 $ 1,887
Black-Scholes option pricing model fair value assumptions	The following assumptions were used to calculate the estimated fair value of awards granted for the periods ended: For the three months ended For the nine months ended October 31, October 31, 2019 2018 2019 2018 Expected volatility — 78.8% - 91.0% 68.3% - 70.8% 78.8% - 91.0% Expected term in years — 4.0 - 8.6 4.0 - 8.6 Risk-free interest rate — 2.72% - 3.10% 1.88% - 2.51% 2.72% - 3.10% Expected dividend yield — — — —	Year ended January 31, 2019 2018 Expected volatility 78.8% - 91.0% 83.9% - 96.8% Expected term in years 4.0 6.0 - 9.39 Risk-free interest rate 2.43% - 2.98% 1.80% - 2.70% Expected dividend yield — —

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Oct. 31, 2019
LEASES
Schedule of future minimum payments under our operating lease	The future minimum payments under the Company’s operating lease as of October 31, 2019 are as follows (in thousands): Operating Lease Fiscal years ending January 31, 2020 $ 92 2021 372 2022 382 2023 392 2024 334 Total future minimum lease payments 1,572 Less: present value discount (486) Present value of operating lease liabilities $ 1,086
Schedule of financing lease commitment	The following table summarizes the Company’s financing lease commitment as of October 31, 2019 (in thousands): Financing Leases Fiscal years ending January 31, 2020 $ 11 2021 43 2022 22 2023 5 Total $ 81

DESCRIPTION OF BUSINESS AND _10

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Apr. 25, 2019$ / sharesshares	Oct. 31, 2019subsidiary$ / sharesshares	Oct. 31, 2018shares	Oct. 31, 2019subsidiary$ / sharesshares	Oct. 31, 2018shares	Jan. 31, 2019subsidiary$ / sharesshares	Jan. 31, 2018$ / sharesshares
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of wholly owned subsidiaries | subsidiary		1		1		1
Conversion reverse stock split ratio	0.04
Number of fractional shares issued	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.001	$ 0.001		$ 0.001		$ 0.001	$ 0.001
Net Loss Per Share
Unvested restricted common stock shares		7,733	7,733	7,733	7,733	193,333	193,333
Potentially dilutive securities excluded from computation of diluted loss per share				6,325,000	7,604,000	182,702,000	215,810,000

DESCRIPTION OF BUSINESS AND _11

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncement (Details) - USD ($) $ in Thousands	Oct. 31, 2019	Feb. 01, 2019
Recent Accounting Pronouncements
Operating lease asset	$ 1,002	$ 1,200
Operating lease discount rate		15.00%
Operating lease liability	$ 1,086	$ 1,300

GOING CONCERN (Details)_2

GOING CONCERN (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2017
GOING CONCERN
Cash and cash equivalents	$ 1,427		$ 1,427		$ 3,069	$ 7,576	$ 6,501
Working capital	300		300		1,100
Net loss	2,113	$ 4,390	8,380	$ 13,200	17,256	16,638
Accumulated deficit	$ 86,916		$ 86,916		$ 78,534	$ 61,278

FAIR VALUE MEASUREMENTS (Deta_2

FAIR VALUE MEASUREMENTS (Details) - Level 1 - Money Market Funds - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Fair Value Measurements
Securities	$ 1.3	$ 2.5
Unrealized gains (losses)	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Fai_2

FAIR VALUE MEASUREMENTS - Fair Value of Warrant Liability Classified as Level 3 Liabilities (Details) - Level 3 - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Jan. 31, 2018
Fair Value of Warrant Liability Classified as Level 3 Liabilities
Beginning balance		$ 11	$ 39	$ 403
Change in fair value of warrants	$ (2)	(9)	(28)	(364)
Ending balance		$ 2	$ 11	$ 39

BALANCE SHEET DETAILS (Detail_2

BALANCE SHEET DETAILS (Details) - USD ($) $ in Thousands	Oct. 31, 2019	Feb. 01, 2019	Jan. 31, 2019	Jan. 31, 2018
Accrued expenses and other current liabilities:
Compensation	$ 417		$ 371	$ 368
Operating lease liability - current portion	260	$ 300
Research and development	119		399	404
Other	67		164	$ 170
Accrued expenses and other current liabilities	$ 863		$ 934

STOCKHOLDERS_ EQUITY - Common S

STOCKHOLDERS? EQUITY - Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			9 Months Ended
	Mar. 31, 2019	Jul. 31, 2017	Apr. 30, 2017	Oct. 31, 2019	May 31, 2019	Apr. 25, 2019	Jan. 31, 2019	Jan. 31, 2018
Proceeds from the issuance of common stock, net of issuance costs				$ 7,200
Common stock, par value				$ 0.001		$ 0.001	$ 0.001	$ 0.001
Aggregate offering price				450,000,000			450,000,000	450,000,000
Private placement
Number of shares issued	1,745,800	5,500,000	6,410,258
Proceeds from the issuance of common stock, net of issuance costs	$ 3,600	$ 1,900	$ 4,400
Share price (in dollars per share)	$ 0.09	$ 0.36	$ 0.78
Sales Agreement | JonesTrading
Number of shares issued				4,747,812
Proceeds from the issuance of common stock, net of issuance costs				$ 3,600
Common stock, par value					$ 0.001
Aggregate offering price					8,500,000

STOCKHOLDERS_ EQUITY - Preferre

STOCKHOLDERS? EQUITY - Preferred Stock & Warrants (Details)

Nov. 20, 2018USD ($)shares

Oct. 23, 2017USD ($)$ / sharesshares

Oct. 31, 2018USD ($)

Jan. 31, 2019USD ($)$ / sharesshares

Jan. 31, 2018USD ($)shares

Oct. 31, 2019$ / sharesshares

Mar. 31, 2019$ / shares

Nov. 20, 2018$ / shares

Nov. 20, 2018shares

Nov. 20, 2018

Nov. 20, 2018item

Nov. 24, 2017$ / shares

Jul. 31, 2017$ / shares

Apr. 30, 2017$ / sharesshares

Sep. 30, 2016

Sep. 30, 2016$ / shares

Sep. 30, 2016shares

Sep. 30, 2016

Sep. 30, 2016USD ($)

Sep. 30, 2016item

Equity

Proceeds from warrant exercises to purchase common stock | $

$ 6,961,000

$ 10,546,000

$ 644,000

Series A convertible preferred stock, shares authorized

10,000,000

10,000,000

10,000,000

Series A convertible preferred stock, shares issued

0

0

0

Incremental fair value of warrants | $

$ 874,000

$ 151,000

Private placement

Equity

Share price (in dollars per share) | $ / shares

$ 0.09

$ 0.36

$ 0.78

Warrants exercise price (in dollars per share) | $ / shares

$ 0.90

Number of shares of common stock subject to warrant (in shares)

3,365,385

Warrant

Equity

Warrants outstanding

4,936,129

Warrant | Series B Warrants

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 6.25

$ 3.50

Issuance of common stock due to exercise of warrants (in shares)

1,066,670

Warrant | New Warrants

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 4.10

Warrants expiry after number of months from issuance

30 months

Warrants exercisable period after anniversary of issuance (in months)

6 months

Warrant | New Warrants | Maximum

Equity

Number of shares of common stock subject to warrant (in shares)

1,066,670

Warrants related to September to November 2014 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 92.50

Warrants outstanding

19,762

Warrants related to June 2015 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 2.75

$ 68.75

Warrants outstanding

109,091

4,363

Warrants related to April 2016 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 1.20

$ 30

Warrants outstanding

1,952,000

70,581

Warrants related to September 2016 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.75

$ 18.75

$ 18.75

Warrant liability | $

$ 11,000

$ 566,000

Number of shares of common stock subject to warrant (in shares)

51,466

Warrants outstanding

1,286,501

51,466

Warrants related to September 2016 financing | Warrant | Risk-free interest rate

Equity

Warrants, measurement input

1.1

1.1

Warrants related to September 2016 financing | Warrant | Contractual term

Equity

Warrants, contractual term

5 years

Warrants related to September 2016 financing | Warrant | Expected volatility

Equity

Warrants, measurement input

95.8

95.8

Warrants related to September 2016 financing | Warrant | Dividend rate

Equity

Warrants, measurement input

0

0

Warrants related to November 2016 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.35

$ 8.75

Warrants outstanding

30,406,061

1,216,230

Warrants related to November 2016 financing, tranche two | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.44

$ 10.938

Warrants outstanding

895,450

35,818

Warrants related to November 2016 financing, tranche three | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.33

$ 8.25

Warrants outstanding

198,214

7,926

Warrants related to April 2017 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.90

$ 22.50

Warrants outstanding

801,282

32,053

Warrants related to October 2017 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.24

$ 0.30

$ 7.50

Number of shares of common stock subject to warrant (in shares)

2,564,103

Warrants outstanding

3,846,152

153,848

Incremental fair value of warrants | $

$ 151,000

Warrants related to October 2017 financing | Warrant | Risk-free interest rate

Equity

Warrants, measurement input

2.03

Warrants related to October 2017 financing | Warrant | Contractual term

Equity

Warrants, contractual term

5 years

Warrants related to October 2017 financing | Warrant | Expected volatility

Equity

Warrants, measurement input

83.9

Warrants related to October 2017 financing | Warrant | Dividend rate

Equity

Warrants, measurement input

0

Warrants related to November 2017 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.20

$ 5

Warrants outstanding

56,935,191

2,277,412

Warrants related to November 2017 financing, tranche two | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.25

Warrants outstanding

33,422,061

Incremental fair value of warrants | $

$ 874,000

Warrants related to November 2017 financing, tranche two | Warrant | Risk-free interest rate

Equity

Warrants, measurement input

2.51

Warrants related to November 2017 financing, tranche two | Warrant | Contractual term

Equity

Warrants, contractual term

6 months

Warrants related to November 2017 financing, tranche two | Warrant | Expected volatility

Equity

Warrants, measurement input

78.4

78.4

Warrants related to November 2017 financing, tranche two | Warrant | Dividend rate

Equity

Warrants, measurement input

0

0

Warrants related To November 2018 financing | Warrant

Equity

Warrants exercise price (in dollars per share) | $ / shares

$ 0.164

$ 4.10

Warrants outstanding

26,666,666

1,066,670

STOCKHOLDERS_ EQUITY - Equity I

STOCKHOLDERS? EQUITY - Equity Incentive Plan (Details) - 2016 Equity Incentive Plan - shares	1 Months Ended		9 Months Ended	12 Months Ended
	Aug. 31, 2018	Mar. 31, 2017	Oct. 31, 2019	Jan. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award
Additional shares authorized	2,000,000	800,000
Number of shares reserved for issuance	2,960,000	960,000
Options
Share-based Compensation Arrangement by Share-based Payment Award
Expiration period			10 years	10 years
Minimum | Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period			1 year	1 year
Maximum | Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period			4 years	4 years

STOCKHOLDERS_ EQUITY - Stock Op

STOCKHOLDERS? EQUITY - Stock Option Activities (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended			9 Months Ended	12 Months Ended
	Aug. 31, 2018	Mar. 31, 2017	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2017
Weighted Average Exercise Prices
Granted							$ 0.12	$ 0.21
The Plans
Available for Grant
Available for grant, beginning			1,507,589	2,160,035	2,107,575	2,107,575	1,884,878	252,379
Shares authorized for issuance							50,000,000	20,000,000
Granted				(877,100)	(16,720)		(10,444,000)	(18,553,000)
Available for grant, ending			1,612,728	1,507,589	2,160,035	1,612,728	2,107,575	1,884,878	252,379
Shares
Outstanding, Beginning			1,481,444	835,338	917,945	917,945	24,724,663	6,465,829
Granted				877,100	16,720		10,444,000	18,553,000
Exercised				0	(1,667)		(278,196)	(40,000)
Outstanding, Ending			1,364,827	1,481,444	835,338	1,364,827	917,945	24,724,663	6,465,829
Vested and exercisable			421,764			421,764	9,257,545
Vested and expected to vest			1,137,123			1,137,123	21,836,056
Weighted Average Exercise Prices
Outstanding, Beginning			$ 4.44	$ 8.27	$ 9.02	$ 9.02	$ 0.41	$ 0.77
Granted				0.80	3.21		0.21	0.29
Exercised					2.50		0.10	0.25
Outstanding, Ending			3.93	$ 4.44	$ 8.27	3.93	9.02	$ 0.41	$ 0.77
Vested and exercisable			7.56			7.56	0.53
Vested and expected to vest			$ 4.26			$ 4.26	$ 0.37
Remaining Contractual Life
Outstanding			8 years 11 months 12 days	8 years 7 months 13 days	8 years 4 months 6 days		7 years 11 months 1 day	9 years 2 months 1 day	8 years 9 months 7 days
Vested and exercisable			8 years 18 days				5 years 11 months 5 days
Vested and expected to vest			8 years 10 months 13 days				7 years 10 months 6 days
Aggregate Intrinsic Value
Outstanding							$ 23	$ 304	$ 238
2014 Equity Incentive Plan
Available for Grant
Canceled			11,478	6,340	28,480
Shares
Canceled			(11,478)	(6,340)	(28,480)
Weighted Average Exercise Prices
Canceled			$ 28.13	$ 13.06	$ 28.27
2016 Equity Incentive Plan
Available for Grant
Shares authorized for issuance	2,000,000	800,000
Canceled			105,139	224,654	69,180		11,262,538	185,499
Shares
Canceled			(105,139)	(224,654)	(69,180)		(11,262,538)	(185,499)
Weighted Average Exercise Prices
Canceled			$ 8.54	$ 4.18	$ 8.84		$ 0.30	$ 0.65
Outside of the 2016 Equity Incentive Plan
Available for Grant
Canceled			8,250	750	6,000
Shares
Outstanding, Beginning			24,250	25,000	31,000	31,000
Canceled			(8,250)	(750)	(6,000)
Outstanding, Ending			16,000	24,250	25,000	16,000	31,000
Vested and exercisable			6,667			6,667
Vested and expected to vest			13,819			13,819
Weighted Average Exercise Prices
Outstanding, Beginning			$ 12.40	$ 12.85	$ 17.86	$ 17.86
Canceled			27.25	27.25	38.75
Outstanding, Ending			4.75	$ 12.40	$ 12.85	4.75	$ 17.86
Vested and exercisable			4.75			4.75
Vested and expected to vest			$ 4.75			$ 4.75
Remaining Contractual Life
Outstanding			8 years 3 months 4 days	5 years 8 months 9 days	7 years 11 months 1 day		6 years 7 months 6 days
Vested and exercisable						8 years 3 months 4 days
Vested and expected to vest						8 years 3 months 4 days
Outside of the 2016 Equity Incentive Plan | First anniversary
Available for Grant
Vesting percentage						25.00%
Outside of the 2016 Equity Incentive Plan | Subsequent to first anniversary
Available for Grant
Vesting percentage						2.083%

STOCKHOLDERS_ EQUITY - Range of

STOCKHOLDERS? EQUITY - Range of Exercise Price (Details) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Jul. 31, 2019	Apr. 30, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Options Outstanding
Number Outstanding (in shares)				1,380,827		23,722,869
Weighted Average Remaining Contractual Life				8 years 11 months 9 days		7 years 10 months 17 days
Weighted Average Exercise Prices (in dollars per share)				$ 3.94		$ 0.37
Options Exercisable
Number Vested and Exercisable (in shares)				428,431		9,590,357
Weighted Average Exercise Prices (in dollars per share)				$ 7.52		$ 0.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Total intrinsic value of options exercised			$ 24,000		$ 26,000	$ 26,000	$ 4,000
The Plans
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Exercised	0	1,667				278,196	40,000
$0.44 - $0.84
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)				0.44		$ 0.10
Exercise prices, high end of range (in dollars per share)				$ 0.84		$ 0.16
Options Outstanding
Number Outstanding (in shares)				758,134		5,503,893
Weighted Average Remaining Contractual Life				9 years 7 months 13 days		8 years 1 month 2 days
Weighted Average Exercise Prices (in dollars per share)				$ 0.79		$ 0.11
Options Exercisable
Number Vested and Exercisable (in shares)				104,257		2,619,037
Weighted Average Exercise Prices (in dollars per share)				$ 0.81		$ 0.10
$0.85 - $4.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)				0.85		0.17
Exercise prices, high end of range (in dollars per share)				$ 4		$ 0.35
Options Outstanding
Number Outstanding (in shares)				109,639		11,347,484
Weighted Average Remaining Contractual Life				8 years 29 days		9 years 7 days
Weighted Average Exercise Prices (in dollars per share)				$ 2.56		$ 0.22
Options Exercisable
Number Vested and Exercisable (in shares)				81,389		1,728,162
Weighted Average Exercise Prices (in dollars per share)				$ 2.54		$ 0.23
$4.01 - $10.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)				4.01		0.36
Exercise prices, high end of range (in dollars per share)				$ 10.50		$ 0.65
Options Outstanding
Number Outstanding (in shares)				410,769		2,567,126
Weighted Average Remaining Contractual Life				8 years 7 months 2 days		6 years 1 month 13 days
Weighted Average Exercise Prices (in dollars per share)				$ 5.60		$ 0.53
Options Exercisable
Number Vested and Exercisable (in shares)				154,321		1,974,108
Weighted Average Exercise Prices (in dollars per share)				$ 5.88		$ 0.53
$10.51- $18.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)				10.51		0.66
Exercise prices, high end of range (in dollars per share)				$ 18.50		$ 1.14
Options Outstanding
Number Outstanding (in shares)				78,244		3,266,554
Weighted Average Remaining Contractual Life				6 years 5 months 9 days		6 years 5 months 5 days
Weighted Average Exercise Prices (in dollars per share)				$ 16.79		$ 0.78
Options Exercisable
Number Vested and Exercisable (in shares)				64,510		2,265,302
Weighted Average Exercise Prices (in dollars per share)				$ 16.72		$ 0.79
$18.51 - $28.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)				18.51		1.15
Exercise prices, high end of range (in dollars per share)				$ 28.50		$ 3
Options Outstanding
Number Outstanding (in shares)				9,600		1,037,812
Weighted Average Remaining Contractual Life				5 years 8 months 27 days		3 years 3 months
Weighted Average Exercise Prices (in dollars per share)				$ 21.79		$ 1.79
Options Exercisable
Number Vested and Exercisable (in shares)				9,600		1,003,748
Weighted Average Exercise Prices (in dollars per share)				$ 21.79		$ 1.80
$28.51 - $75.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)				28.51
Exercise prices, high end of range (in dollars per share)				$ 75
Options Outstanding
Number Outstanding (in shares)				14,441
Weighted Average Remaining Contractual Life				5 years 6 months 7 days
Weighted Average Exercise Prices (in dollars per share)				$ 51.12
Options Exercisable
Number Vested and Exercisable (in shares)				14,354
Weighted Average Exercise Prices (in dollars per share)				$ 51.19
Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Total intrinsic value of options exercised				$ 1,000

STOCK-BASED COMPENSATION - Ex_2

STOCK-BASED COMPENSATION - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Share-based Compensation
Stock-based compensation expense	$ 229	$ 718	$ 597	$ 1,757	$ 2,061	$ 1,887
Total compensation costs not yet recognized	1,000		$ 1,000		$ 2,000
Average remaining amortization period for recognition of expense			2 years 3 months 18 days		2 years 8 months 19 days
Research and development
Share-based Compensation
Stock-based compensation expense	30	166	$ 218	525	$ 654	545
Sales and marketing
Share-based Compensation
Stock-based compensation expense	12	114	45	355	414	393
General and administrative
Share-based Compensation
Stock-based compensation expense	$ 187	$ 438	$ 334	$ 877	$ 993	$ 949

STOCK-BASED COMPENSATION - As_2

STOCK-BASED COMPENSATION - Assumptions (Details) - $ / shares	3 Months Ended	9 Months Ended		12 Months Ended
	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award
Grant date fair value of stock options granted		$ 0.44
Expected term in years		4 years		4 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award
Expected volatility	78.80%	68.30%	78.80%	78.80%	83.90%
Expected term in years	4 years		4 years		6 years
Risk-free interest rate	2.72%	1.88%	2.72%	2.43%	1.80%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award
Expected volatility	91.00%	70.80%	91.00%	91.00%	96.80%
Expected term in years	8 years 7 months 6 days		8 years 7 months 6 days		9 years 4 months 21 days
Risk-free interest rate	3.10%	2.51%	3.10%	2.98%	2.70%

INCOME TAXES (Details)_2

INCOME TAXES (Details) - USD ($)	Oct. 31, 2019	Jan. 31, 2019
INCOME TAXES
Liability for unrecognized tax benefits	$ 0	$ 0

LEASES (Details)

LEASES (Details)	Feb. 01, 2019USD ($)	Oct. 31, 2019USD ($)	Oct. 31, 2018USD ($)	Oct. 31, 2019USD ($)	Oct. 31, 2018USD ($)	Oct. 30, 2018ft²
LEASES
Operating lease asset	$ 1,200,000	$ 1,002,000		$ 1,002,000
Short-term operating lease liabilities	300,000	260,000		260,000
Long-term operating lease liabilities	$ 1,000,000	826,000		826,000
Renewal options, operating lease	true
Renewal term, operating lease	36 months
Operating lease expense		93,000	$ 160,000	278,000	$ 480,000
Cash paid		$ 91,000		$ 246,000
San Jose, California
LEASES
Leased office and laboratory area | ft²						11,793

LEASES - Future minimum payment

LEASES - Future minimum payments (Details) - USD ($) $ in Thousands	Oct. 31, 2019	Feb. 01, 2019
Future minimum payments under operating lease
2020	$ 92
2021	372
2022	382
2023	392
2024	334
Total future minimum lease payments	1,572
Less: present value discount	(486)
Present value of operating lease liabilities	$ 1,086	$ 1,300

LEASES - Financing Lease Commit

LEASES - Financing Lease Commitments (Details) - USD ($)	9 Months Ended
	Oct. 31, 2019	May 31, 2019	Jan. 31, 2019	Mar. 31, 2018	Jan. 31, 2018
Financing lease commitments
2020	$ 11,000
2021	43,000
2022	22,000
2023	5,000
Total	81,000
Leased asset value	186,000		$ 148,000		$ 109,000
Total future payments of interest	$ 7,000
Laboratory Equipment
Financing lease commitments
Leased asset value		$ 54,000		$ 61,000